rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2019-3-40rsp-2814Research ArticleСтатьиArticlesПерспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеванияхPROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASESНасоновЕ. Л.NasonovE L.

34A, Kashirskoe Shosse, Moscow 115522

8, Trubetskaya St., Build. 2, Moscow 119991

nasonov@irramn.ruБекетоваТ. В.BeketovaT. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

АнаньеваЛ. П.AnanyevaL. P.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ВасильевВ. И.VasilyevV. I.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

СоловьевС. К.SolovyevS. K.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

АвдееваА. С.AvdeevaA. S.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation201924122019570приложение 1140Copyright © Насонов Е.Л., Бекетова Т.В., Ананьева Л.П., Васильев В.И., Соловьев С.К., Авдеева А.С., 20192019Насонов Е.Л., Бекетова Т.В., Ананьева Л.П., Васильев В.И., Соловьев С.К., Авдеева А.С.Nasonov e.L., Beketova T.V., Ananyeva L.P., Vasilyev V.I., Solovyev S.K., Avdeeva A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2814иммуновоспалительные (аутоиммунные) ревматические заболеванияВ-клеткиритуксимаббелимумаббиоаналогиАцеллбияimmuno-inflammatory rheumatis diseasesB-cellsrituximabbelimumabbiosimilarsAcellbiaReferencesНасонов ЕЛ, Александрова ЕН, Новиков АА. Аутоиммунные ревматические заболевания – проблемы иммунопатологии и персонифицированной терапии. Вестник Российской академии медицинских наук. 2015;70(2):169-82Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune rheumatic diseases – problems of immunopathology and personalized therapy. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2015;70(2):169-82 (In Russ.).Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369-95. doi: 10.1111/joim.12395Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369-95. doi: 10.1111/joim.12395Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-19 doi: 10.14412/1995-4484-2017-409-419Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):409-19 (In Russ.). doi: 10.14412/1995-4484-2017-409-419Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. doi: 10.1172/JCI78088Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. doi: 10.1172/JCI78088Theofilopoulos AN, Kono DH, Baccala R. The Multiple Pathways to Autoimmunity. Nat Immunol. 2017;18:716-24. doi: 10.1038/ni.3731Theofilopoulos AN, Kono DH, Baccala R. The Multiple Pathways to Autoimmunity. Nat Immunol. 2017;18:716-24. doi: 10.1038/ni.3731Melchers F. Checkpoints that control B cell development. J Clin Invest. 2015;125:2203-10. doi: 10.1172/JCI78083Melchers F. Checkpoints that control B cell development. J Clin Invest. 2015;125:2203-10. doi: 10.1172/JCI78083Rubin SJS, Bloom MS, Robinson WH. B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol. 2019;15(5):303-15. doi: 10.1038/s41584-019-0211-0Rubin SJS, Bloom MS, Robinson WH. B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol. 2019;15(5):303-15. doi: 10.1038/s41584-019-0211-0Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194-202. doi: 10.1172/JCI78084Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194-202. doi: 10.1172/JCI78084Jennewein MF, Alter G. The Immunoregulatory Roles of Antibody Glycosylation. Trends Immunol. 2017;38(5):358-72. doi: 10.1016/j.it.2017.02.004Jennewein MF, Alter G. The Immunoregulatory Roles of Antibody Glycosylation. Trends Immunol. 2017;38(5):358-72. doi: 10.1016/j.it.2017.02.004Forestier A, Guerrier T, Jouvray M, et al. Altered B lymphocyte homeostasis and functions in systemic sclerosis. Autoimmun Rev. 2018;17(3):244-55. doi: 10.1016/j.autrev.2017.10.015Forestier A, Guerrier T, Jouvray M, et al. Altered B lymphocyte homeostasis and functions in systemic sclerosis. Autoimmun Rev. 2018;17(3):244-55. doi: 10.1016/j.autrev.2017.10.015Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjö gren syndrome. Nat Rev Rheumatol. 2018;14(3):133-45. doi: 10.1038/nrrheum.2018.1Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjö gren syndrome. Nat Rev Rheumatol. 2018;14(3):133-45. doi: 10.1038/nrrheum.2018.1Von Borstel A, Sanders JS, Rutgers A, et al. Cellular immune regulation in the pathogenesis of ANCA-associated vasculitides. Autoimmun Rev. 2018 Apr;17(4):413-21. doi: 10.1016/j.autrev.2017.12.002Von Borstel A, Sanders JS, Rutgers A, et al. Cellular immune regulation in the pathogenesis of ANCA-associated vasculitides. Autoimmun Rev. 2018 Apr;17(4):413-21. doi: 10.1016/j.autrev.2017.12.002Dö rner T, Lipsky PE. Beyond pan-B-cell-directed therapy – new avenues and insights into the pathogenesis of SLE. Nat Rev Rheumatol. 2016 Nov;12(11):645-57. doi: 10.1038/nrrheum.2016.158Dö rner T, Lipsky PE. Beyond pan-B-cell-directed therapy – new avenues and insights into the pathogenesis of SLE. Nat Rev Rheumatol. 2016 Nov;12(11):645-57. doi: 10.1038/nrrheum.2016.158Franks SE, Getahun A, Hogarth PM, Cambier JC. Targeting B cells in treatment of autoimmunity. Curr Opin Immunol. 2016 Dec;43:39-45. doi: 10.1016/j.coi.2016.09.003Franks SE, Getahun A, Hogarth PM, Cambier JC. Targeting B cells in treatment of autoimmunity. Curr Opin Immunol. 2016 Dec;43:39-45. doi: 10.1016/j.coi.2016.09.003Marshall MJE, Stopforth RJ, Cragg MS. Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? Front Immunol. 2017;4(8):1245. doi: 10.3389/fimmu.2017.01245Marshall MJE, Stopforth RJ, Cragg MS. Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? Front Immunol. 2017;4(8):1245. doi: 10.3389/fimmu.2017.01245Hofmann K, Clauder AK, Manz RA. Targeting B cells and plasma cells in autoimmune diseases. Front Immunol. 2018 Apr 23;9:835. doi: 10.3389/fimmu.2018.00835Hofmann K, Clauder AK, Manz RA. Targeting B cells and plasma cells in autoimmune diseases. Front Immunol. 2018 Apr 23;9:835. doi: 10.3389/fimmu.2018.00835Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМАПРЕСС; 2012. С. 119-52Nasonov EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: focus on rituximab]. Moscow: IMAPRESS; 2012. P. 119-52 (In Russ.).Насонов ЕЛ. Перспективы анти-В-клеточной терапии в ревматологии. Научно-практическая ревматология. 2018;56(5):539-48 doi: 10.14412/1995-4484-2018-539-548Nasonov EL. Prospects for anti-B-cell therapy in rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):539-48 (In Russ.). doi: 10.14412/1995-4484-2018-539-548Sakkas LI, Daoussis D, Mavropoulos A, et al. Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases. Semin Arthritis Rheum. 2019;48(6):1133-41. doi: 10.1016/j.semarthrit.2018.10.007Sakkas LI, Daoussis D, Mavropoulos A, et al. Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases. Semin Arthritis Rheum. 2019;48(6):1133-41. doi: 10.1016/j.semarthrit.2018.10.007Taha R, El-Haddad H, Almuallim A, et al. Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schö nlein purpura, ankylosing spondylitis, and Raynaud's phenomenon. Open Access Rheumatol. 2017 Dec 15;9:201-14. doi: 10.2147/OARRR.S149373Taha R, El-Haddad H, Almuallim A, et al. Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schö nlein purpura, ankylosing spondylitis, and Raynaud's phenomenon. Open Access Rheumatol. 2017 Dec 15;9:201-14. doi: 10.2147/OARRR.S149373Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017;8(1):12. doi: 10.1007/s13317-017-0100-yDu FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017;8(1):12. doi: 10.1007/s13317-017-0100-yMd Yusof MY, Shaw D, El-Sherbiny YM, et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017;76(11):1829-36. doi: 10.1136/annrheumdis-2017-211191Md Yusof MY, Shaw D, El-Sherbiny YM, et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017;76(11):1829-36. doi: 10.1136/annrheumdis-2017-211191Masoud S, McAdoo SP, Bedi R, et al. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology (Oxford). 2018 Mar 19. doi: 10.1093/rheumatology/key042Masoud S, McAdoo SP, Bedi R, et al. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology (Oxford). 2018 Mar 19. doi: 10.1093/rheumatology/key042Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365-73. doi: 10.1038/nrrheum.2014.33Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365-73. doi: 10.1038/nrrheum.2014.33Sanz I. Connective tissue diseases: targeting B cells in SLE: good news at last! Nat Rev Rheumatol. 2011;7(5):255-6. doi: 10.1038/nrrheum.2011.48Sanz I. Connective tissue diseases: targeting B cells in SLE: good news at last! Nat Rev Rheumatol. 2011;7(5):255-6. doi: 10.1038/nrrheum.2011.48Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-Пресс; 2013. 552 с.Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. 552 p..Кусевич ДА, Авдеева АС. Эффективность и безопасность применения ритуксимаба при ревматоидном артрите (новые данные). Научно-практическая ревматология. 2017;55(4):420-8 doi: 10.14412/1995-4484-2017-420-428Kusevich DA, Avdeeva AS. The efficacy and safety of rituximab in rheumatoid arthritis: New evidence. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):420-8 (In Russ.). doi: 10.14412/1995-4484-2017-420-428Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheumatol Ther. 2015;2(2):99-111. doi: 10.1007/s40744-015-0016-9Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheumatol Ther. 2015;2(2):99-111. doi: 10.1007/s40744-015-0016-9Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77. doi: 10.1136/annrheumdis-2016-210715Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77. doi: 10.1136/annrheumdis-2016-210715Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. 456 с.Nasonov EL, editor. Revmatologiya. Rossiyskie klinicheskie rekomendatsii [Rheumatology. Russian Clinical Recommendations]. Moscow: GEOTAR-Media; 2017. 456 p..Chatzidionysiou K, Lie E, Nasonov E, Lukina G, et al. Highest clinical effectiveness of Rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70:1575-80. doi: 10.1136/ard.2010.148759Chatzidionysiou K, Lie E, Nasonov E, Lukina G, et al. Highest clinical effectiveness of Rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70:1575-80. doi: 10.1136/ard.2010.148759Isaacs JD, Cohen SB, Emery P, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis. 2013;72(3):329-36. doi: 10.1136/annrheumdis-2011-201117Isaacs JD, Cohen SB, Emery P, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis. 2013;72(3):329-36. doi: 10.1136/annrheumdis-2011-201117Авдеева АС, Кусевич ДА. Роль лабораторных биомаркеров в прогнозировании эффективности терапии ритуксимабом при ревматоидном артрите (новые данные). Научно-практическая ревматология. 2017;55(3):295-303 doi: 10.14412/1995-4484-2017-295-303Avdeeva AS, Kusevich DA. The role of laboratory biomarkers in predicting the efficiency of rituximab therapy for rheumatoid arthritis: New evidence. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):295-303 (In Russ.). doi: 10.14412/1995-4484-2017-295-303Cuppen BV, Welsing PM, Sprengers JJ, et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology (Oxford). 2016;55(5):826-39. doi: 10.1093/rheumatology/kev421Cuppen BV, Welsing PM, Sprengers JJ, et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology (Oxford). 2016;55(5):826-39. doi: 10.1093/rheumatology/kev421Scherer HU, Huizinga TWJ, Krö nke G, et al. The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nat Rev Rheumatol. 2018;14(3):157-69. doi: 10.1038/nrrheum.201Scherer HU, Huizinga TWJ, Krö nke G, et al. The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nat Rev Rheumatol. 2018;14(3):157-69. doi: 10.1038/nrrheum.201Razawy W, van Driel M, Lubberts E. The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling. Eur J Immunol. 2018;48(2):220-9. doi: 10.1002/eji.201646787Razawy W, van Driel M, Lubberts E. The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling. Eur J Immunol. 2018;48(2):220-9. doi: 10.1002/eji.201646787Pfeifle R, Rothe T, Ipseiz N, et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol. 2017;18:104-13. doi: 10.1038/ni.3579Pfeifle R, Rothe T, Ipseiz N, et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol. 2017;18:104-13. doi: 10.1038/ni.3579Van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The antiCD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011;63(6):1507-16. doi: 10.1002/art.30314Van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The antiCD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011;63(6):1507-16. doi: 10.1002/art.30314Alunno A, Carubbi F, Bistoni O, et al. Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjö gren's syndrome: a pilot study. Clin Exp Immunol. 2016;184(3):284-92. doi: 10.1111/cei.12771Alunno A, Carubbi F, Bistoni O, et al. Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjö gren's syndrome: a pilot study. Clin Exp Immunol. 2016;184(3):284-92. doi: 10.1111/cei.12771Molendijk M, Hazes JM, Lubberts E. From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis? RMD Open. 2018;4(1):e000256. doi: 10.1136/rmdopen-2016-000256Molendijk M, Hazes JM, Lubberts E. From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis? RMD Open. 2018;4(1):e000256. doi: 10.1136/rmdopen-2016-000256Насонов ЕЛ. Проблемы иммунопатологии ревматоидного артрита: эволюция болезни. Научно-практическая ревматология. 2017;55(3):277-94 doi: 10.14412/1995-4484-2017-277-294Nasonov EL. Problems of rheumatoid arthritis immunopathology: Evolution of the disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):277-94 (In Russ.). doi: 10.14412/1995-4484-2017-277-294Gerlag DM, Safy M, Maijer KI, et al. A single infusion of rituximab delays the onset of arthritis in subjects at high risk of developing RA [abstract]. Arthritis Rheum. 2016;68 Suppl 10.Gerlag DM, Safy M, Maijer KI, et al. A single infusion of rituximab delays the onset of arthritis in subjects at high risk of developing RA [abstract]. Arthritis Rheum. 2016;68 Suppl 10.Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi: 10.1002/art.37715Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi: 10.1002/art.37715Food and Drug Administration [webpage on the Internet]. Questions and Answers on Rituximab (added 12/19/2006). Available from: https://wayback.archiveit.org/7993/20170722191606/; https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109107.htm. Accessed August 9, 2017.Food and Drug Administration [webpage on the Internet]. Questions and Answers on Rituximab (added 12/19/2006). Available from: https://wayback.archiveit.org/7993/20170722191606/; https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109107.htm. Accessed August 9, 2017.Lally L, Spiera R. B-cell-targeted therapy in systemic vasculitis. Curr Opin Rheumatol. 2016;28(1):15-20. doi: 10.1097/BOR.0000000000000235Lally L, Spiera R. B-cell-targeted therapy in systemic vasculitis. Curr Opin Rheumatol. 2016;28(1):15-20. doi: 10.1097/BOR.0000000000000235McClure M, Gopaluni S, Jayne D, Jones R. B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. Nat Rev Rheumatol. 2018;14(10):580-91. doi: 10.1038/s41584-018-0065-xMcClure M, Gopaluni S, Jayne D, Jones R. B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. Nat Rev Rheumatol. 2018;14(10):580-91. doi: 10.1038/s41584-018-0065-xStone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-32. doi: 10.1056/NEJMoa0909905Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-32. doi: 10.1056/NEJMoa0909905Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417-27. doi: 10.1056/NEJMoa1213277Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417-27. doi: 10.1056/NEJMoa1213277Miloslavsky EM, Specks U, Merkel PA, et al. Rituximab for the treatment of relapses in ANCA-associated vasculitis. Arthritis Rheum. 2014;66(11):3151-9. doi: 10.1002/art.38788Miloslavsky EM, Specks U, Merkel PA, et al. Rituximab for the treatment of relapses in ANCA-associated vasculitis. Arthritis Rheum. 2014;66(11):3151-9. doi: 10.1002/art.38788Geetha D, Specks U, Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol. 2015;26(4):976-85. doi: 10.1681/ASN.2014010046Geetha D, Specks U, Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol. 2015;26(4):976-85. doi: 10.1681/ASN.2014010046Fussner LA, Hummel AM, Schroeder DR, et al. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheum. 2016;68(7):1700-10. doi: 10.1002/art.39637Fussner LA, Hummel AM, Schroeder DR, et al. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheum. 2016;68(7):1700-10. doi: 10.1002/art.39637Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-20. doi: 10.1056/NEJMoa0909169Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-20. doi: 10.1056/NEJMoa0909169Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015;74(6):1178-82. doi: 10.1136/annrheumdis-2014-206404Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015;74(6):1178-82. doi: 10.1136/annrheumdis-2014-206404Walsh M, Flossmann O, Berden A, et al; European Vasculitis Study Group. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:542-8. doi: 10.1002/art.33361Walsh M, Flossmann O, Berden A, et al; European Vasculitis Study Group. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:542-8. doi: 10.1002/art.33361Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum. 2012;64:3760-9. doi: 10.1002/art.34583Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum. 2012;64:3760-9. doi: 10.1002/art.34583Bunch DO, McGregor JG, Khandoobhai NB, et al. Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol. 2013;8:382-91. doi: 10.2215/CJN.03950412Bunch DO, McGregor JG, Khandoobhai NB, et al. Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol. 2013;8:382-91. doi: 10.2215/CJN.03950412Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771-80. doi: 10.1056/NEJMoa1404231Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771-80. doi: 10.1056/NEJMoa1404231Terrier B, Pagnoux C, Perrodeau E, et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis. 2018;77(8):1150-6. doi: 10.1136/annrheumdis-2017-21Terrier B, Pagnoux C, Perrodeau E, et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis. 2018;77(8):1150-6. doi: 10.1136/annrheumdis-2017-21Gopaluni S, Smith RM, Lewin M, et al. Rituximab versus azathioprine as therapy for maintenance of remission for anti- neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials. 2017 Mar 7. doi: 10.1186/s13063-017-1857-zGopaluni S, Smith RM, Lewin M, et al. Rituximab versus azathioprine as therapy for maintenance of remission for anti- neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials. 2017 Mar 7. doi: 10.1186/s13063-017-1857-zCharles P, Terrier B, Perrodeau E, et al; French Vasculitis Study Group. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1143-9. doi: 10.1136/annrheumdis-2017-212878Charles P, Terrier B, Perrodeau E, et al; French Vasculitis Study Group. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1143-9. doi: 10.1136/annrheumdis-2017-212878Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2015;54(7):1153-60. doi: 10.1093/rheumatology/keu452Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2015;54(7):1153-60. doi: 10.1093/rheumatology/keu452Recillas-Gispert C, Serna-Ojeda JC, Flores-Suarez LF. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's). Graefes Arch Clin Exp Ophthalmol. 2015;253(12):2279-84. doi: 10.1007/s00417-015-3198-5Recillas-Gispert C, Serna-Ojeda JC, Flores-Suarez LF. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's). Graefes Arch Clin Exp Ophthalmol. 2015;253(12):2279-84. doi: 10.1007/s00417-015-3198-5Henderson SR, Copley SJ, Pusey CD, et al. Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA). Medicine (Baltimore). 2014;93(27):e229. doi: 10.1097/MD.0000000000000229Henderson SR, Copley SJ, Pusey CD, et al. Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA). Medicine (Baltimore). 2014;93(27):e229. doi: 10.1097/MD.0000000000000229Umezawa N, Kohsaka H, Nanki T, et al. Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIg. Mod Rheumatol. 2014;24(4):685-7. doi: 10.3109/14397595.2013.874734Umezawa N, Kohsaka H, Nanki T, et al. Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIg. Mod Rheumatol. 2014;24(4):685-7. doi: 10.3109/14397595.2013.874734Thiel J, Hassler F, Salzer U, et al. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther. 2013;15(5):R133. doi: 10.1186/ar4313Thiel J, Hassler F, Salzer U, et al. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther. 2013;15(5):R133. doi: 10.1186/ar4313Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (ChurgStrauss) Ann Rheum Dis. 2016;75(2):396-401. doi: 10.1136/annrheumdis-2014-206095Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (ChurgStrauss) Ann Rheum Dis. 2016;75(2):396-401. doi: 10.1136/annrheumdis-2014-206095Teixeira V, Mohammad AJ, Jones RB, et al. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019 Jun 5;5(1):e000905. doi: 10.1136/rmdopen-2019-000905Teixeira V, Mohammad AJ, Jones RB, et al. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019 Jun 5;5(1):e000905. doi: 10.1136/rmdopen-2019-000905Wendt M, Gunnarsson I, Bratt J, Bruchfeld A. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scand J Rheumatol. 2012;41(2):116-9. doi: 10.3109/03009742.2011.620573Wendt M, Gunnarsson I, Bratt J, Bruchfeld A. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scand J Rheumatol. 2012;41(2):116-9. doi: 10.3109/03009742.2011.620573Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 2012;64(11):3770-8. doi: 10.1002/art.34584Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 2012;64(11):3770-8. doi: 10.1002/art.34584Pendergraft WF, Cortazar FB, Wenger J, et al. Long-term maintenance therapy using rituximab-induced continuous B-Cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol. 2014;9(4):736-44. doi: 10.2215/CJN.07340713Pendergraft WF, Cortazar FB, Wenger J, et al. Long-term maintenance therapy using rituximab-induced continuous B-Cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol. 2014;9(4):736-44. doi: 10.2215/CJN.07340713Charles P, Neel A, Tieulie N, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford). 2014;53(3):532-9. doi: 10.1093/rheumatology/ket381Charles P, Neel A, Tieulie N, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford). 2014;53(3):532-9. doi: 10.1093/rheumatology/ket381Nagafuchi H, Atsumi T, Hatta K, et al. Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis. Mod Rheumatol. 2015;25(4):603-8. doi: 10.3109/14397595.2014.981945Nagafuchi H, Atsumi T, Hatta K, et al. Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis. Mod Rheumatol. 2015;25(4):603-8. doi: 10.3109/14397595.2014.981945Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol. 2010;5(8):1394-400. doi: 10.2215/CJN.08821209Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol. 2010;5(8):1394-400. doi: 10.2215/CJN.08821209Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol. 2012;39(1):125-30. doi: 10.3899/jrheum.110143Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol. 2012;39(1):125-30. doi: 10.3899/jrheum.110143Calich AL, Puechal X, Pugnet G, et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's): results of a single-center cohort study on 66 patients. J Autoimmun. 2014;50:135-41. doi: 10.1016/j.jaut.2014.03.002Calich AL, Puechal X, Pugnet G, et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's): results of a single-center cohort study on 66 patients. J Autoimmun. 2014;50:135-41. doi: 10.1016/j.jaut.2014.03.002Cortazar FB, Muhsin SA, Pendergraft WF 3rd, et al. Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis. Kidney Int Rep. 2017;3(2):394-402. doi: 10.1016/j.ekir.2017.11.004Cortazar FB, Muhsin SA, Pendergraft WF 3rd, et al. Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis. Kidney Int Rep. 2017;3(2):394-402. doi: 10.1016/j.ekir.2017.11.004Cortazar FB, Pendergraft WF 3rd, Wenger J, et al. Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2017;69(5):1045-53. doi: 10.1002/art.40032Cortazar FB, Pendergraft WF 3rd, Wenger J, et al. Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2017;69(5):1045-53. doi: 10.1002/art.40032Ананьева ЛП, Соловьев СК, Бекетова ТВ и др. Анти-Вклеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно-практическая ревматология. 2014;52(5):495-506 doi: 10.14412/1995-4484-2014-495-506Ananieva LP, Soloviyov SK, Beketova TV, et al. Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):495-506 (In Russ.). doi: 10.14412/1995-4484-2014-495-506Бекетова ТВ, Александрова ЕН, Новоселова ТМ и др. Российский опыт применения моноклональных антител к В-лимфоцитам (ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научнопрактическая ревматология. 2014;52(2):147-58 doi: 10.14412/1995-4484-2014-147-158Beketova TV, Aleksandrova EN, Novoselova TM, et al. Russian experience with using monoclonal antibodies to B lymphocytes (rituximab) in systemic vasculitides associated with neutrophil cytoplasmic antibodies (preliminary results of the Russian Register NORMA). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):147-58 (In Russ.). doi: 10.14412/1995-4484-2014-147-158Donnithorne KJ, Atkinson TP, Hinze CH, et al. Rituximab therapy for severe refractory chronic Henoch-Schö nlein purpura. J Pediatr. 2009;155(1):136-9. doi: 10.1016/j.jpeds.2008.12.049Donnithorne KJ, Atkinson TP, Hinze CH, et al. Rituximab therapy for severe refractory chronic Henoch-Schö nlein purpura. J Pediatr. 2009;155(1):136-9. doi: 10.1016/j.jpeds.2008.12.049Pillebout E, Rocha F, Fardet L, et al. Successful outcome using rituximab as the only immunomodulation in Henoch-Schö nlein purpura: case report. Nephrol Dial Transplant. 2011;26(6):2044-6. doi: 10.1093/ndt/gfr137Pillebout E, Rocha F, Fardet L, et al. Successful outcome using rituximab as the only immunomodulation in Henoch-Schö nlein purpura: case report. Nephrol Dial Transplant. 2011;26(6):2044-6. doi: 10.1093/ndt/gfr137Maritati F, Fenoglio R, Pillebout E, et al. Brief report: Rituximab for the treatment of adult-onset IgA vasculitis (HenochSchö nlein). Arthritis Rheum. 2018;70(1):109-14. doi: 10.1002/art.40339Maritati F, Fenoglio R, Pillebout E, et al. Brief report: Rituximab for the treatment of adult-onset IgA vasculitis (HenochSchö nlein). Arthritis Rheum. 2018;70(1):109-14. doi: 10.1002/art.40339Lundberg S, Westergren E, Smolander J, Bruchfeld A. B celldepleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. Clin Kidney J. 2017;10(1):20-6. doi: 10.1093/ckj/sfw106Lundberg S, Westergren E, Smolander J, Bruchfeld A. B celldepleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. Clin Kidney J. 2017;10(1):20-6. doi: 10.1093/ckj/sfw106Fenoglio R, Naretto C, Basolo B, et al. Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature. Immunol Res. 2017;65(1):186-92. doi: 10.1007/s12026-016-8827-5Fenoglio R, Naretto C, Basolo B, et al. Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature. Immunol Res. 2017;65(1):186-92. doi: 10.1007/s12026-016-8827-5Bellan M, Pirisi M, Sainaghi PP. Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schö nlein purpura with rituximab. Scand J Rheumatol. 2016;45(1):83-4. doi: 10.3109/03009742.2015.1058417Bellan M, Pirisi M, Sainaghi PP. Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schö nlein purpura with rituximab. Scand J Rheumatol. 2016;45(1):83-4. doi: 10.3109/03009742.2015.1058417Pindi Sala T, Michot JM, Snanoudj R, et al. Successful outcome of a corticodependent Henoch-Schö nlein purpura adult with rituximab. Case Rep Med. 2014;2014:619218. doi: 10.1155/2014/619218Pindi Sala T, Michot JM, Snanoudj R, et al. Successful outcome of a corticodependent Henoch-Schö nlein purpura adult with rituximab. Case Rep Med. 2014;2014:619218. doi: 10.1155/2014/619218Crayne CB, Eloseily E, Mannion ML, et al. Rituximab treatment for chronic steroid-dependent Henoch-Schö nlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J. 2018;16(1):71. doi: 10.1186/s12969-018-0285Crayne CB, Eloseily E, Mannion ML, et al. Rituximab treatment for chronic steroid-dependent Henoch-Schö nlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J. 2018;16(1):71. doi: 10.1186/s12969-018-0285Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):835-42. doi: 10.1002/art.34322Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):835-42. doi: 10.1002/art.34322Saadoun D, Rigon MR, Sene D, et al. Rituximab plus PEGinterferon-/ribavirin compared with PEG-interferon-/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326-34. doi: 10.1182/blood-2009-10-248518Saadoun D, Rigon MR, Sene D, et al. Rituximab plus PEGinterferon-/ribavirin compared with PEG-interferon-/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326-34. doi: 10.1182/blood-2009-10-248518Saadoun D, Resche-Rigon M, Sene D, et al. Rituximab combined with PEG-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis. 2008;67(10):1431-6. doi: 10.1136/ard.2007.081653Saadoun D, Resche-Rigon M, Sene D, et al. Rituximab combined with PEG-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis. 2008;67(10):1431-6. doi: 10.1136/ard.2007.081653De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843-53. doi: 10.1002/art.34331De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843-53. doi: 10.1002/art.34331Terrier B, Saadoun D, Sene D, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup [sic] study of thirty-two patients. Arthritis Rheum. 2009;60(8):2531-40. doi: 10.1002/art.24703Terrier B, Saadoun D, Sene D, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup [sic] study of thirty-two patients. Arthritis Rheum. 2009;60(8):2531-40. doi: 10.1002/art.24703Dammacco F, Tucci FA, Lauletta G, et al. PEGylated interferon-, ribavirin, and rituximab combined therapy of hepatitis C virusrelated mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343-53. doi: 10.1182/blood-2009-10-245878Dammacco F, Tucci FA, Lauletta G, et al. PEGylated interferon-, ribavirin, and rituximab combined therapy of hepatitis C virusrelated mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343-53. doi: 10.1182/blood-2009-10-245878Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev. 2011;10(11):714-9. doi: 10.1016/j.autrev.2011.04.033Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev. 2011;10(11):714-9. doi: 10.1016/j.autrev.2011.04.033Visentini M, Tinelli C, Colantuono S, et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. Autoimmun Rev. 2015;14(10):889-96. doi: 10.1016/j.autrev.2015.05.013Visentini M, Tinelli C, Colantuono S, et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. Autoimmun Rev. 2015;14(10):889-96. doi: 10.1016/j.autrev.2015.05.013Petrarca A, Rigacci L, Monti M, et al. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. Dig Liver Dis. 2007;39(Suppl 1):S129-S133. doi: 10.1016/S1590-8658(07)80025-9Petrarca A, Rigacci L, Monti M, et al. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. Dig Liver Dis. 2007;39(Suppl 1):S129-S133. doi: 10.1016/S1590-8658(07)80025-9Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003;62(12):1230-3. doi: 10.1136/ard.2002.004929Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003;62(12):1230-3. doi: 10.1136/ard.2002.004929Roccatello D, Sciascia S, Rossi D, et al. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. Oncotarget. 2017;8(25):41764-77. doi: 10.18632/oncotarget.16986Roccatello D, Sciascia S, Rossi D, et al. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. Oncotarget. 2017;8(25):41764-77. doi: 10.18632/oncotarget.16986Saadoun D, Pineton de Chambrun M, Hermine O, et al. Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma. Arthritis Care Res (Hoboken). 2013;65(4):643-7. doi: 10.1002/acr.21856Saadoun D, Pineton de Chambrun M, Hermine O, et al. Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma. Arthritis Care Res (Hoboken). 2013;65(4):643-7. doi: 10.1002/acr.21856Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929-39. doi: 10.1056/NEJMra071297Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929-39. doi: 10.1056/NEJMra071297Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6(6):326-37. doi: 10.1038/nrrheum.2010.68Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6(6):326-37. doi: 10.1038/nrrheum.2010.68Dö rner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344-58. doi: 10.1016/S0140-6736(19)30546-XDö rner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344-58. doi: 10.1016/S0140-6736(19)30546-XKansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019;11(482):eaav1648. doi: 10.1126/scitranslmed.aav1648Kansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019;11(482):eaav1648. doi: 10.1126/scitranslmed.aav1648Durcan L, O'Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332-43. doi: 10.1016/S0140-6736(19)30237-5Durcan L, O'Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332-43. doi: 10.1016/S0140-6736(19)30237-5Murphy G, Isenberg DA. New therapies for systemic lupus erythematosus – past imperfect, future tense. Nat Rev Rheumatol. 2019;15(7):403-12. doi: 10.1038/s41584-019-0235-5Murphy G, Isenberg DA. New therapies for systemic lupus erythematosus – past imperfect, future tense. Nat Rev Rheumatol. 2019;15(7):403-12. doi: 10.1038/s41584-019-0235-5Sanz I. Systemic lupus erythematosus: Extent and patterns of offlabel use of rituximab for SLE. Nat Rev Rheumatol. 2016;12(12):700-2. doi: 10.1038/nrrheum.2016.191Sanz I. Systemic lupus erythematosus: Extent and patterns of offlabel use of rituximab for SLE. Nat Rev Rheumatol. 2016;12(12):700-2. doi: 10.1038/nrrheum.2016.191Kleinmann JF, Tubach F, Le Guern V, et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev. 2017;16(6):650-7. doi: 10.1016/j.autrev.2017.04.011Kleinmann JF, Tubach F, Le Guern V, et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev. 2017;16(6):650-7. doi: 10.1016/j.autrev.2017.04.011Felten R, Dervovic E, Chasset F, et al. The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. Autoimmun Rev. 2018;17(8):781-90. doi: 10.1016/j.autrev.2018.02.011Felten R, Dervovic E, Chasset F, et al. The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. Autoimmun Rev. 2018;17(8):781-90. doi: 10.1016/j.autrev.2018.02.011Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018 Jan 1;57(1):e1-e45. doi: 10.1093/rheumatology/kex286Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018 Jan 1;57(1):e1-e45. doi: 10.1093/rheumatology/kex286Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-45. doi: 10.1136/annrheumdis-2019-215089Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemicPons-Estel BA, Bonfa E, Soriano ER, et al. Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR). First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis. 2018;77(11):1549-57. doi: 10.1136/annrheumdis-2018-213512lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-45. doi: 10.1136/annrheumdis-2019-215089Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222-33. doi: 10.1002/art.27233Pons-Estel BA, Bonfa E, Soriano ER, et al. Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR). First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis. 2018;77(11):1549-57. doi: 10.1136/annrheumdis-2018-213512Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011;20:709-16. doi: 10.1177/0961203310395802Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222-33. doi: 10.1002/art.27233Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-26. doi: 10.1002/art.34359Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011;20:709-16. doi: 10.1177/0961203310395802Isenberg DA, Merrill JT. Why, why, why de-lupus (does so badly in clinical trials). Expert Rev Clin Immunol. 2016;2:95-8. doi: 10.1586/1744666X.2016.1112270Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-26. doi: 10.1002/art.34359Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after Rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-9. doi: 10.2215/CJN.01070118Isenberg DA, Merrill JT. Why, why, why de-lupus (does so badly in clinical trials). Expert Rev Clin Immunol. 2016;2:95-8. doi: 10.1586/1744666X.2016.1112270Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology. 2005;44(12):1542-5. doi: 10.1093/rheumatology/kei080Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after Rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-9. doi: 10.2215/CJN.01070118Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009;61(4):482-7. doi: 10.1002/art.24341Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology. 2005;44(12):1542-5. doi: 10.1093/rheumatology/kei080Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357-64. doi: 10.1016/j.autrev.2011.10.009Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009;61(4):482-7. doi: 10.1002/art.24341Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280-6. doi: 10.1136/annrheumdis-2012-202844Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357-64. doi: 10.1016/j.autrev.2011.10.009Witt M, Grunke M, Proft F, et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus. 2013;22(11):1142-9. doi: 10.1177/0961203313503912Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280-6. doi: 10.1136/annrheumdis-2012-202844Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67(12):1724-31. doi: 10.1136/ard.2007.083162Witt M, Grunke M, Proft F, et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus. 2013;22(11):1142-9. doi: 10.1177/0961203313503912Lindholm C, Borjesson-Asp K, Zendjanchi K, et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008;35(5):826-33.Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67(12):1724-31. doi: 10.1136/ard.2007.083162Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28(4):468-76.Lindholm C, Borjesson-Asp K, Zendjanchi K, et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008;35(5):826-33.Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011;63(10):3038-47. doi: 10.1002/art.30466Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28(4):468-76.Fernandez-Nebro A, de la Fuente JL, Carreno L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus. 2012;21(10):1063-76. doi: 10.1177/0961203312446627Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011;63(10):3038-47. doi: 10.1002/art.30466Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8):2458-66. doi: 10.1002/art.27541Fernandez-Nebro A, de la Fuente JL, Carreno L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus. 2012;21(10):1063-76. doi: 10.1177/0961203312446627Pinto LF, Velasquez CJ, Prieto C, et al. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus. 2011;20(11):1219-26. doi: 10.1177/0961203311409273Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8):2458-66. doi: 10.1002/art.27541Wang CR, Weng CT, Liu MF. Monocentric experience of the rituximab therapy in systemic lupus erythematosus-associated antiphospholipid syndrome with warfarin therapy failure. Semin Arthritis Rheum. 2017;47(1):e7-e8. doi: 10.1016/j.semarthrit.2017.03.012Pinto LF, Velasquez CJ, Prieto C, et al. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus. 2011;20(11):1219-26. doi: 10.1177/0961203311409273McCarthy EM, Sutton E, Nesbit S, et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology (Oxford). 2018;57(3):470-9. doi: 10.1093/rheumatology/kex395Wang CR, Weng CT, Liu MF. Monocentric experience of the rituximab therapy in systemic lupus erythematosus-associated antiphospholipid syndrome with warfarin therapy failure. Semin Arthritis Rheum. 2017;47(1):e7-e8. doi: 10.1016/j.semarthrit.2017.03.012Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2016;4(1):e000182. doi: 10.1136/lupus-2016-000182McCarthy EM, Sutton E, Nesbit S, et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology (Oxford). 2018;57(3):470-9. doi: 10.1093/rheumatology/kex395Chavarot N, Verhelst D, Pardon A, et al; Groupe Cooperatif sur le Lupus Renal. Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. Medicine (Baltimore). 2017;96(27):e7429. doi: 10.1097/MD.0000000000007429Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2016;4(1):e000182. doi: 10.1136/lupus-2016-000182Aguiar R, Araujo C, Martins-Coelho G, et al. Use of Rituximab in systemic lupus erythematosus: a single Center experience over 14 years. Arthritis Care Res. 2017;69:257-62. doi: 10.1002/acr.22921Chavarot N, Verhelst D, Pardon A, et al; Groupe Cooperatif sur le Lupus Renal. Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. Medicine (Baltimore). 2017;96(27):e7429. doi: 10.1097/MD.0000000000007429Iwata S, Saito K, Hirata S, et al. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus. 2018 Apr;27(5):802-11. doi: 10.1177/0961203317749047Aguiar R, Araujo C, Martins-Coelho G, et al. Use of Rituximab in systemic lupus erythematosus: a single Center experience over 14 years. Arthritis Care Res. 2017;69:257-62. doi: 10.1002/acr.22921Торгашина АВ, Соловьев СК, Александрова ЕН и др. Применение ритуксимаба у больных волчаночным нефритом. Научно-практическая ревматология. 2010;48(4):14-26 doi: 10.14412/1995-4484-2010-1161Iwata S, Saito K, Hirata S, et al. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus. 2018 Apr;27(5):802-11. doi: 10.1177/0961203317749047Tsanyan ME, Soloviev SK, Radenska-Lopovok SG, et al. Clinical and morphological improvement of lupus nephritis treated with Rituximab. Folia Medica. 2014;56:245. doi: 10.1515/folmed-2015-0003Torgashina AV, Solovyev SK, Aleksandrova EN, et al. Use of rituximab in patients with lupus nephritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2010;48(4):14-26 (In Russ.). doi: 10.14412/1995-4484-2010-1161Chen H, Zheng W, Su J, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology. 2011;50:1640-4. doi: 10.1093/rheumatology/ker176Tsanyan ME, Soloviev SK, Radenska-Lopovok SG, et al. Clinical and morphological improvement of lupus nephritis treated with Rituximab. Folia Medica. 2014;56:245. doi: 10.1515/folmed-2015-0003Niaz FA, Aleem A. Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Saudi J Kidney Dis Transplant. 2010;21:109.Chen H, Zheng W, Su J, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology. 2011;50:1640-4. doi: 10.1093/rheumatology/ker176Gupta R, Ezeonyeji A, Thomas A, et al. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: Responseto rituximab and cyclophosphamide. Lupus. 2011;20:1547-50. doi: 10.1177/0961203311411349Niaz FA, Aleem A. Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Saudi J Kidney Dis Transplant. 2010;21:109.Sardesai VV, Sardesai VR, Agarwal TD. Steroid-resistant autoimmune thrombocytopenia in systemic lupus erythematosus treated with rituximab. Indian J Dermatol. 2015;60:106. doi: 10.4103/0019-5154.147874Gupta R, Ezeonyeji A, Thomas A, et al. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: Responseto rituximab and cyclophosphamide. Lupus. 2011;20:1547-50. doi: 10.1177/0961203311411349Jovancevic B, Lindholm C, Pullerits R. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. Lupus. 2013;22:664-74. doi: 10.1177/0961203313485489Sardesai VV, Sardesai VR, Agarwal TD. Steroid-resistant autoimmune thrombocytopenia in systemic lupus erythematosus treated with rituximab. Indian J Dermatol. 2015;60:106. doi: 10.4103/0019-5154.147874Boyero RG, Esteve EM, Esteve MM, et al. Systemic lupus erythematosus and thrombotic thrombocytopenia purpura: a refractory case without lupus activity. Reumatol Clin. 2013;9:373-5. doi: 10.1016/j.reumae.2012.11.006Jovancevic B, Lindholm C, Pullerits R. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. Lupus. 2013;22:664-74. doi: 10.1177/0961203313485489Serris A, Amoura Z, Canoui-Poitrine F, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. Am J Hematol. 2018 Mar;93(3):424-9. doi: 10.1002/ajh.24999Boyero RG, Esteve EM, Esteve MM, et al. Systemic lupus erythematosus and thrombotic thrombocytopenia purpura: a refractory case without lupus activity. Reumatol Clin. 2013;9:373-5. doi: 10.1016/j.reumae.2012.11.006Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470-5. doi: 10.1136/ard.2006.057885Serris A, Amoura Z, Canoui-Poitrine F, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. Am J Hematol. 2018 Mar;93(3):424-9. doi: 10.1002/ajh.24999Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41:364-72. doi: 10.1016/j.semarthrit.2011.06.004Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470-5. doi: 10.1136/ard.2006.057885Aakjaer S, Bendstrup E, Ivarsen P, Madsen LB. Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndrome. Respir Med Case Rep. 2017 Sep 30;22:263-5. doi: 10.1016/j.rmcr.2017.09.012Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41:364-72. doi: 10.1016/j.semarthrit.2011.06.004Dioszegi A, Tarr T, Nagy-Vincze M, et al. Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. Lupus. 2018 Aug;27(9):1552-8. doi: 10.1177/0961203318768890Aakjaer S, Bendstrup E, Ivarsen P, Madsen LB. Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndrome. Respir Med Case Rep. 2017 Sep 30;22:263-5. doi: 10.1016/j.rmcr.2017.09.012Bakshi J, Hassan S, D'Cruz D, Chan A. Rituximab therapy in refractory macrophage activation syndrome secondary to systemic lupus erythematosus. Lupus. 2013;22:1544-6. doi: 10.1177/0961203313504634Dioszegi A, Tarr T, Nagy-Vincze M, et al. Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. Lupus. 2018 Aug;27(9):1552-8. doi: 10.1177/0961203318768890Wang CR, Liu MF, Weng CT, et al. Systemic lupus erythematosus-associated diffuse alveolar haemorrhage: a single-centre experience in Han Chinese patients. Scand J Rheumatol. 2018 Sep;47(5):392-9. doi: 10.1080/03009742.2017.1420817Bakshi J, Hassan S, D'Cruz D, Chan A. Rituximab therapy in refractory macrophage activation syndrome secondary to systemic lupus erythematosus. Lupus. 2013;22:1544-6. doi: 10.1177/0961203313504634Montes-Rivera G, Rios G, Vila LM. Efficacy of Rituximab in a systemic lupus erythematosus patient presenting with diffuse alveolar hemorrhage. Case Rep Rheumatol. 2017;2017:6031053. doi: 10.1155/2017/6031053Wang CR, Liu MF, Weng CT, et al. Systemic lupus erythematosus-associated diffuse alveolar haemorrhage: a single-centre experience in Han Chinese patients. Scand J Rheumatol. 2018 Sep;47(5):392-9. doi: 10.1080/03009742.2017.1420817Quelhas da Costa R, Aguirre-Alastuey ME, Isenberg DA, Saracino AM. Assessment of response to B-cell depletion using Rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018;154(12):1432-40. doi: 10.1001/jamadermatol.2018.3793Montes-Rivera G, Rios G, Vila LM. Efficacy of Rituximab in a systemic lupus erythematosus patient presenting with diffuse alveolar hemorrhage. Case Rep Rheumatol. 2017;2017:6031053. doi: 10.1155/2017/6031053Parodis I, Lopez Benavides AH, Zickert A, et al. The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23718Quelhas da Costa R, Aguirre-Alastuey ME, Isenberg DA, Saracino AM. Assessment of response to B-cell depletion using Rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018;154(12):1432-40. doi: 10.1001/jamadermatol.2018.3793Peterknecht E, Keasey MP, Beresford MW. The effectiveness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE): A systematic review. Lupus. 2018;27(13):2135-45. doi: 10.1177/0961203318804879Parodis I, Lopez Benavides AH, Zickert A, et al. The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23718Mahmoud I, Jellouli M, Boukhris I, et al. Efficacy and safety of Rituximab in the management of pediatric systemic lupus erythematosus: A systematic review. J Pediatr. 2017;187:213-9.e2. doi: 10.1016/j.jpeds.2017.05.002Peterknecht E, Keasey MP, Beresford MW. The effectiveness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE): A systematic review. Lupus. 2018;27(13):2135-45. doi: 10.1177/0961203318804879Basu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol. 2017;32(6):1013-21. doi: 10.1007/s00467-017-3583-xMahmoud I, Jellouli M, Boukhris I, et al. Efficacy and safety of Rituximab in the management of pediatric systemic lupus erythematosus: A systematic review. J Pediatr. 2017;187:213-9.e2. doi: 10.1016/j.jpeds.2017.05.002Ishaiki F, Obaid E, Almuallim A, et al. Outcomes of rituximab therapy in refractory lupus: A meta-analysis. Eur J Rheumatol. 2018;5(2):118-26. doi: 10.5152/eurjrheum.2018.17096Basu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol. 2017;32(6):1013-21. doi: 10.1007/s00467-017-3583-xGalarza-Maldonado C, Kourilovitch MR, Molineros JE, et al. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in latin american patients with active systemic lupus erythematosus. Autoimmun Rev. 2010;10:108-11. doi: 10.1016/j.autrev.2010.08.012Ishaiki F, Obaid E, Almuallim A, et al. Outcomes of rituximab therapy in refractory lupus: A meta-analysis. Eur J Rheumatol. 2018;5(2):118-26. doi: 10.5152/eurjrheum.2018.17096Contis A, Vanquaethem H, Truchetet M-E, et al. Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review. Clin Rheumatol. 2016;35:517-22. doi: 10.1007/s10067-015-3166-9Galarza-Maldonado C, Kourilovitch MR, Molineros JE, et al. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in latin american patients with active systemic lupus erythematosus. Autoimmun Rev. 2010;10:108-11. doi: 10.1016/j.autrev.2010.08.012Zhang J, Zhao Z, Hu X. Effect of Rituximab on serum levels of anti-C1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis. Cell Biochem Biophys. 2015;72:197-201. doi: 10.1007/s12013-014-0437-zContis A, Vanquaethem H, Truchetet M-E, et al. Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review. Clin Rheumatol. 2016;35:517-22. doi: 10.1007/s10067-015-3166-9Davies R, Sangle S, Jordan N, et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus. 2013;22:574-82. doi: 10.1177/0961203313483376Zhang J, Zhao Z, Hu X. Effect of Rituximab on serum levels of anti-C1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis. Cell Biochem Biophys. 2015;72:197-201. doi: 10.1007/s12013-014-0437-zMoroni G, Gallelli B, Sinico RA, et al. Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study. Ann Rheum Dis. 2012;71:1751-2. doi: 10.1136/annrheumdis-2012-201442Davies R, Sangle S, Jordan N, et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus. 2013;22:574-82. doi: 10.1177/0961203313483376Turner-Stokes T, Lu TY, Ehrenstein MR, et al. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology. 2011;50:1401-8. doi: 10.1093/rheumatology/ker018Moroni G, Gallelli B, Sinico RA, et al. Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study. Ann Rheum Dis. 2012;71:1751-2. doi: 10.1136/annrheumdis-2012-201442Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011;13:75. doi: 10.1186/ar3337Turner-Stokes T, Lu TY, Ehrenstein MR, et al. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology. 2011;50:1401-8. doi: 10.1093/rheumatology/ker018Andrade-Ortega L, Irazoque-Palazuelos F, Lopez-Villanueva R, et al. Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study. Reumatol Clin. 2010;6:250-5. doi: 10.1016/j.reuma.2009.11.004Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011;13:75. doi: 10.1186/ar3337Boletis JN, Marinaki S, Skalioti C, et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant. 2009;24:2157-60. doi: 10.1093/ndt/gfp002Andrade-Ortega L, Irazoque-Palazuelos F, Lopez-Villanueva R, et al. Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study. Reumatol Clin. 2010;6:250-5. doi: 10.1016/j.reuma.2009.11.004Catapano F, Chaudhry AN, Jones RB, et al. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010;25:3586-92. doi: 10.1093/ndt/gfq256Boletis JN, Marinaki S, Skalioti C, et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant. 2009;24:2157-60. doi: 10.1093/ndt/gfp002Galarza C, Valencia D, Tobon GJ, et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol. 2008;34:124-8. doi: 10.1007/s12016-007-8028-zCatapano F, Chaudhry AN, Jones RB, et al. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010;25:3586-92. doi: 10.1093/ndt/gfq256Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus. 2010;19:213-9. doi: 10.1177/0961203309351541Galarza C, Valencia D, Tobon GJ, et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol. 2008;34:124-8. doi: 10.1007/s12016-007-8028-zGottenberg J-E, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913-20. doi: 10.1136/ard.2004.029694Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus. 2010;19:213-9. doi: 10.1177/0961203309351541Jonsdottir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008;67:330-4. doi: 10.1136/ard.2007.079095Gottenberg J-E, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913-20. doi: 10.1136/ard.2004.029694Lateef A, Lahiri M, Teng G, Vasoo S. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus. 2010;19:765-70. doi: 10.1177/0961203309358599Jonsdottir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008;67:330-4. doi: 10.1136/ard.2007.079095Reynolds J, Toescu V, Yee C, et al. Effects of rituximab on resistant SLE disease including lung involvement. Lupus. 2009;18:67-73. doi: 10.1177/0961203308094653Lateef A, Lahiri M, Teng G, Vasoo S. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus. 2010;19:765-70. doi: 10.1177/0961203309358599Sutter JA, Kwan-Morley J, Dunham J, et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol. 2008;126:282-90. doi: 10.1016/j.clim.2007.11.012Reynolds J, Toescu V, Yee C, et al. Effects of rituximab on resistant SLE disease including lung involvement. Lupus. 2009;18:67-73. doi: 10.1177/0961203308094653Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007;17:191-7. doi: 10.3109/s10165-007-0565Sutter JA, Kwan-Morley J, Dunham J, et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol. 2008;126:282-90. doi: 10.1016/j.clim.2007.11.012Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8:83. doi: 10.1186/ar195Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007;17:191-7. doi: 10.3109/s10165-007-0565Pirone C, Mendoza-Pinto C, van der Windt DA, et al. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review. Semin Arthritis Rheum. 2017 Dec;47(3):384-96. doi: 10.1016/j.semarthrit.2017.04.010Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8:83. doi: 10.1186/ar195Tew GW, Rabbee N, Wolslegel K, et al: Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010;19:146-57. doi: 10.1177/0961203309350752Pirone C, Mendoza-Pinto C, van der Windt DA, et al. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review. Semin Arthritis Rheum. 2017 Dec;47(3):384-96. doi: 10.1016/j.semarthrit.2017.04.010Dias SS, Rodriguez-Garcia V, Nguyen H, et al. Longer duration of B cell depletion is associated with better outcome. Rheumatology (Oxford). 2015;54:1876-81. doi: 10.1093/rheumatology/kev036Tew GW, Rabbee N, Wolslegel K, et al: Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010;19:146-57. doi: 10.1177/0961203309350752Jonsdottir T, Gunnarsson I, Mourao AF, et al. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford). 2010;49:1502-4. doi: 10.1093/rheumatology/keq055Dias SS, Rodriguez-Garcia V, Nguyen H, et al. Longer duration of B cell depletion is associated with better outcome. Rheumatology (Oxford). 2015;54:1876-81. doi: 10.1093/rheumatology/kev036Lazarus MN, Turner-Stokes T, Chavele KM, et al. B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology (Oxford). 2012;51:1208-15. doi: 10.1093/rheumatology/ker526Jonsdottir T, Gunnarsson I, Mourao AF, et al. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford). 2010;49:1502-4. doi: 10.1093/rheumatology/keq055Marquez A, Davila-Fajardo CL, Robledo G, et al. IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. Mol Biol Rep. 2013;40:4851-6. doi: 10.1007/s11033-013-2583-6Lazarus MN, Turner-Stokes T, Chavele KM, et al. B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology (Oxford). 2012;51:1208-15. doi: 10.1093/rheumatology/ker526Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis. 2007;66:259-62. doi: 10.1136/ard.2006.067124Marquez A, Davila-Fajardo CL, Robledo G, et al. IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. Mol Biol Rep. 2013;40:4851-6. doi: 10.1007/s11033-013-2583-6Robledo G, Davila-Fajardo CL, Marquez A, et al. Association between -174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases. DNA Cell Biol. 2012;31:1486-91. doi: 10.1089/dna.2012.1684Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis. 2007;66:259-62. doi: 10.1136/ard.2006.067124Robledo G, Marquez A, Davila-Fajardo CL, et al. Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients. DNA Cell Biol. 2012;31:1671-7. doi: 10.1089/dna.2012.1799Robledo G, Davila-Fajardo CL, Marquez A, et al. Association between -174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases. DNA Cell Biol. 2012;31:1486-91. doi: 10.1089/dna.2012.1684Vital EM, Wittmann M, Edward S, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheum. 2015;67:1586-91. doi: 10.1002/art.39085Robledo G, Marquez A, Davila-Fajardo CL, et al. Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients. DNA Cell Biol. 2012;31:1671-7. doi: 10.1089/dna.2012.1799Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;379(13):1290. doi: 10.1056/NEJMc1Vital EM, Wittmann M, Edward S, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheum. 2015;67:1586-91. doi: 10.1002/art.39085Kumar D, Roubey RAS. Use of Rituximab in the antiphospholipid syndrome. Curr Opin Rheumatol. 2010;12:40-4. doi: 10.1007/s11926-009-0074-5Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;379(13):1290. doi: 10.1056/NEJMc1Erkan D, Vega J, Ramon G, et al. A pilot open label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65:464-71. doi: 10.1002/art.37759Kumar D, Roubey RAS. Use of Rituximab in the antiphospholipid syndrome. Curr Opin Rheumatol. 2010;12:40-4. doi: 10.1007/s11926-009-0074-5Sciascia S, Radin M, Cecchi I, et al. Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome. Semin Arthritis Rheum. 2018 Apr 11. pii: S0049-0172(18)30097-0. doi: 10.1016/j.semarthrit.2018.04.001Erkan D, Vega J, Ramon G, et al. A pilot open label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65:464-71. doi: 10.1002/art.37759Berman H, Rodriguez-Pinto I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085-90. doi: 10.1016/j.autrev.2013.05.004Sciascia S, Radin M, Cecchi I, et al. Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome. Semin Arthritis Rheum. 2018 Apr 11. pii: S0049-0172(18)30097-0. doi: 10.1016/j.semarthrit.2018.04.001Rodriguez-Pinto I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis. 2015;7(1):26-30. doi: 10.1177/1759720X14554793Berman H, Rodriguez-Pinto I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085-90. doi: 10.1016/j.autrev.2013.05.004Dogru A, Ugan Y, Sahin M, et al. Catastrophic antiphospholipid syndrome treated with rituximab: A case report. Eur J Rheumatol. 2017;4(2):145-7. doi: 10.5152/eurjrheum.2017.160073Rodriguez-Pinto I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis. 2015;7(1):26-30. doi: 10.1177/1759720X14554793Gkogkolou P, Ehrchen J, Goerge T. Severe antiphospholipid antibody syndrome – response to plasmapheresis and rituximab. J Dermatolog Treat. 2017;28(6):564-66. doi: 10.1080/09546634.2017.1282599Dogru A, Ugan Y, Sahin M, et al. Catastrophic antiphospholipid syndrome treated with rituximab: A case report. Eur J Rheumatol. 2017;4(2):145-7. doi: 10.5152/eurjrheum.2017.160073Sukara G, Baresic M, Sentic M, et al. Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature. Acta Reumatol Port. 2015;40(2):169-75.Gkogkolou P, Ehrchen J, Goerge T. Severe antiphospholipid antibody syndrome – response to plasmapheresis and rituximab. J Dermatolog Treat. 2017;28(6):564-66. doi: 10.1080/09546634.2017.1282599Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018 Mar;195:76-82. doi: 10.1016/j.imlet.2018.01.002Sukara G, Baresic M, Sentic M, et al. Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature. Acta Reumatol Port. 2015;40(2):169-75.Okamoto M, Okano A, Akamatsu S, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006;20(1):172-3. doi: 10.1038/sj.leu.2403996Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018 Mar;195:76-82. doi: 10.1016/j.imlet.2018.01.002Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60(2):578-83. doi: 10.1002/art.24249Okamoto M, Okano A, Akamatsu S, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006;20(1):172-3. doi: 10.1038/sj.leu.2403996Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up openlabel trial. Arthritis Res Ther. 2010;12(2):R54. doi: 10.1186/ar2965Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60(2):578-83. doi: 10.1002/art.24249Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30(Suppl 71):S17-S22.Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up openlabel trial. Arthritis Res Ther. 2010;12(2):R54. doi: 10.1186/ar2965Smith V, van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69(1):193-7. doi: 10.1136/ard.2008.095463Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30(Suppl 71):S17-S22.Smith V, Piette Y, van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52-7. doi: 10.3899/jrheum.120778Smith V, van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69(1):193-7. doi: 10.1136/ard.2008.095463Moazedi-Fuerst FC, Kielhauser SM, Brickmann K, et al. Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen. Scand J Rheumatol. 2014;43(3):257-8. doi: 10.3109/03009742.2013.869617Smith V, Piette Y, van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52-7. doi: 10.3899/jrheum.120778Giuggioli D, Lumetti F, Colaci M, et al. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015;14(11):1072-8. doi: 10.1016/j.autrev.2015.07.008Moazedi-Fuerst FC, Kielhauser SM, Brickmann K, et al. Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen. Scand J Rheumatol. 2014;43(3):257-8. doi: 10.3109/03009742.2013.869617Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2010;49(2):271-80. doi: 10.1093/rheumatology/kep093Giuggioli D, Lumetti F, Colaci M, et al. Rituximab in the treatment of patients with systemic sclerosis. Our experienceJordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188-94. doi: 10.1136/annrheumdis-2013-204522and review of the literature. Autoimmun Rev. 2015;14(11):1072-8. doi: 10.1016/j.autrev.2015.07.008Bosello SL, De Luca G, Rucco M, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44(4):428-36. doi: 10.1016/j.semarthrit.2014.09.002Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2010;49(2):271-80. doi: 10.1093/rheumatology/kep093Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al. A multi-center, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017;46(5):625-31. doi: 10.1016/j.semarthrit.2016.10.003Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188-94. doi: 10.1136/annrheumdis-2013-204522Thiebaut M, Launay D, Riviere S, et al. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev. 2018;17(6):582-7. doi: 10.1016/j.autrev.2017.12.010Bosello SL, De Luca G, Rucco M, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44(4):428-36. doi: 10.1016/j.semarthrit.2014.09.002Sari A, Guven D, Armagan B, et al. Rituximab experience in patients with long-standing systemic sclerosis-associated interstitial lung disease: A series of 14 patients. J Clin Rheumatol. 2017 Dec;23(8):411-5. doi: 10.1097/RHU.0000000000000Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al. A multi-center, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017;46(5):625-31. doi: 10.1016/j.semarthrit.2016.10.003Melsens K, Vandecasteele E, Deschepper E, et al. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clin Belg. 2018 Apr;73(2):119-25. doi: 10.1080/17843286.2017.1Thiebaut M, Launay D, Riviere S, et al. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev. 2018;17(6):582-7. doi: 10.1016/j.autrev.2017.12.010Boonstra M, Meijs J, Dorjee AL, et al. Rituximab in early systemic sclerosis. RMD Open. 2017 Jul 28;3(2):e000384. doi: 10.1136/rmdopen-2016-0003Sari A, Guven D, Armagan B, et al. Rituximab experience in patients with long-standing systemic sclerosis-associated interstitial lung disease: A series of 14 patients. J Clin Rheumatol. 2017 Dec;23(8):411-5. doi: 10.1097/RHU.0000000000000Lepri G, Avouac J, Airo P, et al. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):181-5.Melsens K, Vandecasteele E, Deschepper E, et al. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clin Belg. 2018 Apr;73(2):119-25. doi: 10.1080/17843286.2017.1Vilela VS, Maretti GB, Gama LM, et al. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center. Rev Bras Reumatol Engl Ed. 2016 Sep-Oct;56(5):458-63. doi: 10.1016/j.rbre.2016.06.003Boonstra M, Meijs J, Dorjee AL, et al. Rituximab in early systemic sclerosis. RMD Open. 2017 Jul 28;3(2):e000384. doi: 10.1136/rmdopen-2016-0003Elhai M, Boubaya M, Distler O, et al; for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78(7):979-87. doi: 10.1136/annrheumdis-2018-214816Lepri G, Avouac J, Airo P, et al. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):181-5.Ананьева ЛП, Конева ОА, Десинова ОВ и др. Влияние ритуксимаба на проявления активности и легочную функцию у больных системной склеродермией: оценка после года наблюдения. Научно-практическая ревматология. 2019;57(3):265-73 doi: 10.14412/1995-4484-2019-265-273Vilela VS, Maretti GB, Gama LM, et al. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center. Rev Bras Reumatol Engl Ed. 2016 Sep-Oct;56(5):458-63. doi: 10.1016/j.rbre.2016.06.003Конева ОА, Десинова ОВ, Ананьева ЛП, Ковалева НВ. Значение компьютерной томографии высокого разрешения в оценке эффективности ритуксимаба у пациентов с интерстициальным поражением легких при системной склеродермии. Научно-практическая ревматология. 2018;56(5):591-9 doi: 10.14412/1995-4484-2018-591-599Elhai M, Boubaya M, Distler O, et al; for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78(7):979-87. doi: 10.1136/annrheumdis-2018-214816Гарзанова ЛА, Ананьева ЛП, Конева ОА, Овсянникова ОБ. Влияние ритуксимаба на поражение сердца при системной склеродермии. Научно-практическая ревматология. 2018;56(6):709-15 doi: 10.14412/1995-4484-2018-709-715Ananyeva LP, Koneva OA, Desinova OV, et al. Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):265-73 (In Russ.). doi: 10.14412/1995-4484-2019-265-273Mariette X, Criswell LA. Primary Sjö gren's syndrome. N Engl J Med. 2018 Mar 8;378(10):931-9. doi: 10.1056/NEJMcp170251Koneva OA, Desinova OV, Ananyeva LP, Kovaleva NV. The importance of high-resolution computed tomography in evaluating the efficacy of rituximab in patients with interstitial lung disease in systemic sclerosis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):591-9 (In Russ.). doi: 10.14412/1995-4484-2018-591-599Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67(11):1541-4. doi: 10.1136/ard.2007.083865Garzanova LA, Ananyeva LP, Koneva OA, Ovsyannikova OB. Effect of rituximab on heart involvement in systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(6):709-15 (In Russ.). doi: 10.14412/1995-4484-2018-709-715Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960-96. doi: 10.1002/art.27314Mariette X, Criswell LA. Primary Sjö gren's syndrome. N Engl J Med. 2018 Mar 8;378(10):931-9. doi: 10.1056/NEJMcp170251Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160(4):233-42. doi: 10.7326/M13-1085Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67(11):1541-4. doi: 10.1136/ard.2007.083865Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15(5):R172. doi: 10.1186/ar4359Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960-96. doi: 10.1002/art.27314Jousse-Joulin S, Devauchelle-Pensec V, Cornec D, et al. Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sjogren's syndrome. Arthritis Rheum. 2015;67(6):1623-8. doi: 10.1002/art.39088Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160(4):233-42. doi: 10.7326/M13-1085Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013;72(6):1026-31. doi: 10.1136/annrheumdis-2012-202293Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15(5):R172. doi: 10.1186/ar4359Meiners PM, Arends S, Meijer JM, et al. Efficacy of retreatment with rituximab in patients with primary Sjogren's syndrome. Clin Exp Rheumatol. 2015;33(3):443-4.Jousse-Joulin S, Devauchelle-Pensec V, Cornec D, et al. Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sjogren's syndrome. Arthritis Rheum. 2015;67(6):1623-8. doi: 10.1002/art.39088Cornec D, Costa S, Devauchelle-Pensec V, et al. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjogren's syndrome. J Autoimmun. 2016;67:102-10. doi: 10.1016/j.jaut.2015.11.002Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013;72(6):1026-31. doi: 10.1136/annrheumdis-2012-202293Delli K, Haacke EA, Kroese FG, et al. Towards personalized treatment in primary Sjogren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. Ann Rheum Dis. 2016;75(11):1933-8. doi: 10.1136/annrheumdis-2015-208304Meiners PM, Arends S, Meijer JM, et al. Efficacy of retreatment with rituximab in patients with primary Sjogren's syndrome. Clin Exp Rheumatol. 2015;33(3):443-4.Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjö gren's syndrome. Arthritis Rheum. 2017;69(7):1440-50. doi: 10.1002/art.40093Cornec D, Costa S, Devauchelle-Pensec V, et al. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjogren's syndrome. J Autoimmun. 2016;67:102-10. doi: 10.1016/j.jaut.2015.11.002Fisher BA, Everett CC, Rout J, et al. Effect of rituximab on a salivary gland ultrasound score in primary Sjö gren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. Ann Rheum Dis. 2018;77(3):412-6. doi: 10.1136/annrheumdis-2017-212268Delli K, Haacke EA, Kroese FG, et al. Towards personalized treatment in primary Sjogren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. Ann Rheum Dis. 2016;75(11):1933-8. doi: 10.1136/annrheumdis-2015-208304Souza FB, Porfirio GJ, Andriolo BN, et al. Rituximab effectiveness and safety for treating primary Sjogren's syndrome (pSS): systematic review and meta-analysis. PLoS One. 2016;11(3):e0150749. doi: 10.1371/journal.pone.0150749Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjö gren's syndrome. Arthritis Rheum. 2017;69(7):1440-50. doi: 10.1002/art.40093Fox RI, Fox CM. Sjogren syndrome: why do clinical trials fail? Rheum Dis Clin North Am. 2016;42(3):519-30. doi: 10.1016/j.rdc.2016.03.009Fisher BA, Everett CC, Rout J, et al. Effect of rituximab on a salivary gland ultrasound score in primary Sjö gren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. Ann Rheum Dis. 2018;77(3):412-6. doi: 10.1136/annrheumdis-2017-212268Letaief H, Lukas C, Barnetche T, et al. Efficacy and safety of biological DMARDs modulating B cells in primary Sjö gren's syndrome: Systematic review and meta-analysis. Joint Bone Spine. 2018 Jan;85(1):15-22. doi: 10.1016/j.jbspin.2017.06.004Souza FB, Porfirio GJ, Andriolo BN, et al. Rituximab effectiveness and safety for treating primary Sjogren's syndrome (pSS): systematic review and meta-analysis. PLoS One. 2016;11(3):e0150749. doi: 10.1371/journal.pone.0150749Moerman RV, Arends S, Meiners PM, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis. 2014;73:472-4. doi: 10.1136/annrheumdis-2013-203736Fox RI, Fox CM. Sjogren syndrome: why do clinical trials fail? Rheum Dis Clin North Am. 2016;42(3):519-30. doi: 10.1016/j.rdc.2016.03.009Moerman RV, Arends S, Meiners PM, et al. Detailed analysis of the articular domain in patients with primary Sjö gren syndrome. J Rheumatol. 2017;44:292-6. doi: 10.3899/jrheum.160459Letaief H, Lukas C, Barnetche T, et al. Efficacy and safety of biological DMARDs modulating B cells in primary Sjö gren's syndrome: Systematic review and meta-analysis. Joint Bone Spine. 2018 Jan;85(1):15-22. doi: 10.1016/j.jbspin.2017.06.004Carsons SE, Vivino FB, Parke A, et al.Treatment guidelines for rheumatologic manifestations of Sjö gren's syndrome: use of biologics, management of fatigue and inflammatory musculoskeletal pain. Arthritis Care Res. 2017;69:517-27. doi: 10.1002/acr.22968Moerman RV, Arends S, Meiners PM, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis. 2014;73:472-4. doi: 10.1136/annrheumdis-2013-203736Verstappen GM, van Nimwegen JF, Vissink A, et al. The value of rituximab treatment in primary Sjö gren's syndrome. Clin Immunol. 2017;182:62-71. doi: 10.1016/j.clim.2017.05.002Moerman RV, Arends S, Meiners PM, et al. Detailed analysis of the articular domain in patients with primary Sjö gren syndrome. J Rheumatol. 2017;44:292-6. doi: 10.3899/jrheum.160459Chen MH, Chen CK, Chou HP, et al. Rituximab therapy in primary Sjogren's syndrome with interstitial lung disease: a retrospective cohort study. Clin Exp Rheumatol. 2016;34(6):1077-84.Carsons SE, Vivino FB, Parke A, et al.Treatment guidelines for rheumatologic manifestations of Sjö gren's syndrome: use of biologics, management of fatigue and inflammatory musculoskeletal pain. Arthritis Care Res. 2017;69:517-27. doi: 10.1002/acr.22968Mekinian A, Ravaud P, Larroche C, et al; Club Rhumatismes et Inflammation. Rituximab in central nervous system manifestations of patients with primary Sjö gren's syndrome: results from the AIR registry. Clin Exp Rheumatol. 2012;30(2):208-12.Verstappen GM, van Nimwegen JF, Vissink A, et al. The value of rituximab treatment in primary Sjö gren's syndrome. Clin Immunol. 2017;182:62-71. doi: 10.1016/j.clim.2017.05.002Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012;71(1):84-7. doi: 10.1136/annrheumdis-2011-200086Chen MH, Chen CK, Chou HP, et al. Rituximab therapy in primary Sjogren's syndrome with interstitial lung disease: a retrospective cohort study. Clin Exp Rheumatol. 2016;34(6):1077-84.Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjö gren's syndrome. Ann Rheum Dis. 2007;66:351-7. doi: 10.1136/ard.2006.057919Mekinian A, Ravaud P, Larroche C, et al; Club Rhumatismes et Inflammation. Rituximab in central nervous system manifestations of patients with primary Sjö gren's syndrome: results from the AIR registry. Clin Exp Rheumatol. 2012;30(2):208-12.Мeiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab. Ann Rheum Dis. 2012;71:1297-302. doi: 10.1136/annrheumdis-2011-200460Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012;71(1):84-7. doi: 10.1136/annrheumdis-2011-200086Nocturne G, Virone A, Ng W-F, et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjö gren's syndrome. Arthritis Rheum. 2016;68:977-85. doi: 10.1002/art.39518Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjö gren's syndrome. Ann Rheum Dis. 2007;66:351-7. doi: 10.1136/ard.2006.057919Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjö gren's syndrome after two infusions of rituximab (antiCD20). Arthritis Rheum. 2007;57:310-7. doi: 10.1002/art.22536Мeiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab. Ann Rheum Dis. 2012;71:1297-302. doi: 10.1136/annrheumdis-2011-200460Clair EW St, Levesque MC, Prak ETL, et al. Autoimmunity centers of excellence, rituximab therapy for primary Sjö gren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013;65:1097-106. doi: 10.1002/art.37850Nocturne G, Virone A, Ng W-F, et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjö gren's syndrome. Arthritis Rheum. 2016;68:977-85. doi: 10.1002/art.39518Verstappen GM, Kroese FGM, Meiners PM, et al. B cell depletion therapy normalizes circulating follicular Th cells in primary Sjogren syndrome. J Rheumatol. 2017;44:49-58. doi: 10.3899/jrheum.160313Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjö gren's syndrome after two infusions of rituximab (antiCD20). Arthritis Rheum. 2007;57:310-7. doi: 10.1002/art.22536Lindop R, Arentz G, Bastian I, et al. Long-term Ro60 humoral autoimmunity in primary Sjö gren's syndrome is maintained by rapid clonal turnover. Clin Immunol. 2013;148:27-34. doi: 10.1016/j.clim.2013.03.015Clair EW St, Levesque MC, Prak ETL, et al. Autoimmunity centers of excellence, rituximab therapy for primary Sjö gren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013;65:1097-106. doi: 10.1002/art.37850Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One. 2013;8:e59868. doi: 10.1371/journal.pone.0059868Verstappen GM, Kroese FGM, Meiners PM, et al. B cell depletion therapy normalizes circulating follicular Th cells in primary Sjogren syndrome. J Rheumatol. 2017;44:49-58. doi: 10.3899/jrheum.160313Pollard RP, Abdulahad WH, Bootsma H, et al. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome. Ann Rheum Dis. 2013;72:2048-50. doi: 10.1136/annrheumdis-2013-203447Lindop R, Arentz G, Bastian I, et al. Long-term Ro60 humoral autoimmunity in primary Sjö gren's syndrome is maintained by rapid clonal turnover. Clin Immunol. 2013;148:27-34. doi: 10.1016/j.clim.2013.03.015Dalakas MC. Inflammatory Muscle Diseases. N Engl J Med. 2015;373(4):393-404. doi: 10.1056/NEJMc1506827Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One. 2013;8:e59868. doi: 10.1371/journal.pone.0059868Ghirardello A, Borella E, Beggio M, et al. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights. 2014;5(3):69-75. doi: 10.1007/s13317-014-0060-4Pollard RP, Abdulahad WH, Bootsma H, et al. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome. Ann Rheum Dis. 2013;72:2048-50. doi: 10.1136/annrheumdis-2013-203447Barsotti S, Cioffi E, Tripoli A, et al. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature. Reumatismo. 2018 Jul 6;70(2):78-84. doi: 10.4081/reumatismo.2Dalakas MC. Inflammatory Muscle Diseases. N Engl J Med. 2015;373(4):393-404. doi: 10.1056/NEJMc1506827Fasano S, Gordon P, Hajji R, et al. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford). 2017 Jan;56(1):26-36. doi: 10.1093/rheumatology/kew146Ghirardello A, Borella E, Beggio M, et al. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights. 2014;5(3):69-75. doi: 10.1007/s13317-014-0060-4Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601-7. doi: 10.1002/art.20849Barsotti S, Cioffi E, Tripoli A, et al. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature. Reumatismo. 2018 Jul 6;70(2):78-84. doi: 10.4081/reumatismo.2Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143:763-7. doi: 10.1001/archderm.143.6.763Fasano S, Gordon P, Hajji R, et al. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford). 2017 Jan;56(1):26-36. doi: 10.1093/rheumatology/kew146Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 2009;48:968-71. doi: 10.1093/rheumatology/kep157Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601-7. doi: 10.1002/art.20849Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 2010;62:1328-34. doi: 10.1002/acr.20219Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143:763-7. doi: 10.1001/archderm.143.6.763Mahler EAM, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology. 2011;50:2206-13. doi: 10.1093/rheumatology/ker088Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 2009;48:968-71. doi: 10.1093/rheumatology/kep157Couderc M, Gottenberg J-E, Mariette X, et al. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology. 2011;50:2283-9. doi: 10.1093/rheumatology/ker305Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 2010;62:1328-34. doi: 10.1002/acr.20219Marie I, Dominique S, Janvresse A, et al. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med. 2012;106:581-7. doi: 10.1016/j.rmed.2012.01.001Mahler EAM, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology. 2011;50:2206-13. doi: 10.1093/rheumatology/ker088Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314-24. doi: 10.1002/art.37754Couderc M, Gottenberg J-E, Mariette X, et al. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology. 2011;50:2283-9. doi: 10.1093/rheumatology/ker305Aggarwal R, Loganathan P, Koontz D, et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2017 Feb;56(2):247-54. doi: 10.1093/rheumatology/kew396Marie I, Dominique S, Janvresse A, et al. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med. 2012;106:581-7. doi: 10.1016/j.rmed.2012.01.001Unger L, Kampf S, Lü thke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology. 2014;53:1630-8. doi: 10.1093/rheumatology/keu024Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314-24. doi: 10.1002/art.37754Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology. 2015;54:1420-8. doi: 10.1093/rheumatology/kev004Aggarwal R, Loganathan P, Koontz D, et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2017 Feb;56(2):247-54. doi: 10.1093/rheumatology/kew396Rider LG, Yip AL, Horkayne-Szakaly I, et al. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clin Exp Rheumatol. 2014;32:689-96.Unger L, Kampf S, Lü thke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology. 2014;53:1630-8. doi: 10.1093/rheumatology/keu024Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19:353-9. doi: 10.1111/resp.12214Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology. 2015;54:1420-8. doi: 10.1093/rheumatology/kev004Allenbach Y, Guiguet M, Rigolet A, et al. Efficacy of Rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: An open-label, phase ii trial. PLoS One. 2015 Nov 5;10(11):e0133702. doi: 10.1371/journal.pone.0133Rider LG, Yip AL, Horkayne-Szakaly I, et al. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clin Exp Rheumatol. 2014;32:689-96.Doyle TJ, Dhillon N, Madan R, et al. Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: A multicenter retrospective case review. J Rheumatol. 2018 Jun;45(6):841-50. doi: 10.3899/jrheum.170541Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19:353-9. doi: 10.1111/resp.12214Khelkovskaya-Sergeeva AN, Antelava OA, Olunin YA, Tarasova GM, Lopatina NE, Palshina SE, Sazhina EG, Nasonov EL. Rituximab in patients with idiopathic inflammatory myopathies associated with interstitial lung disease. Ann Rheum Dis. 2016;75:741-2 [SAT0203].Allenbach Y, Guiguet M, Rigolet A, et al. Efficacy of Rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: An open-label, phase ii trial. PLoS One. 2015 Nov 5;10(11):e0133702. doi: 10.1371/journal.pone.0133Bauhammer J, Blank N, Max R, et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response. J Rheumatol. 2016 Aug;43(8):1566-74. doi: 10.3899/jrheum.15Doyle TJ, Dhillon N, Madan R, et al. Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: A multicenter retrospective case review. J Rheumatol. 2018 Jun;45(6):841-50. doi: 10.3899/jrheum.170541Lambotte O, Kotb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol. 2005;32:1369-70.Khelkovskaya-Sergeeva AN, Antelava OA, Olunin YA, Tarasova GM, Lopatina NE, Palshina SE, Sazhina EG, Nasonov EL. Rituximab in patients with idiopathic inflammatory myopathies associated with interstitial lung disease. Ann Rheum Dis. 2016;75:741-2 [SAT0203].Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol. 2005;11:264-6. doi: 10.1097/01.rhu.0000182155.08982.60Bauhammer J, Blank N, Max R, et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response. J Rheumatol. 2016 Aug;43(8):1566-74. doi: 10.3899/jrheum.15Brulhart L,Waldburger J-M, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis. 2006;65:974-5. doi: 10.1136/ard.2005.045898Lambotte O, Kotb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol. 2005;32:1369-70.Zappa MC, Trequattrini T, Mattioli F et al. Rituximab treatment in a case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failure. Multidiscip Respir Med. 2011;6:183-8. doi: 10.1186/2049-6958-6-3-183Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol. 2005;11:264-6. doi: 10.1097/01.rhu.0000182155.08982.60Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol. 2007;56:148-53. doi: 10.1016/j.jaad.2006.05.068Brulhart L,Waldburger J-M, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis. 2006;65:974-5. doi: 10.1136/ard.2005.045898Bader-Meunier B, Decaluwe H, Barnerias C, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38:1436-40. doi: 10.3899/jrheum.101321Zappa MC, Trequattrini T, Mattioli F et al. Rituximab treatment in a case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failure. Multidiscip Respir Med. 2011;6:183-8. doi: 10.1186/2049-6958-6-3-183Rios Fernandez R, Callejas Rubio J-L, Sanchez Cano D, et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol. 2009;27:1009-16.Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol. 2007;56:148-53. doi: 10.1016/j.jaad.2006.05.068Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheum. 2014;66:740-9. doi: 10.1002/art.38270Bader-Meunier B, Decaluwe H, Barnerias C, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38:1436-40. doi: 10.3899/jrheum.101321Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181-92. doi: 10.1038/modpathol.2012.72Rios Fernandez R, Callejas Rubio J-L, Sanchez Cano D, et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol. 2009;27:1009-16.Седышев СХ, Васильев ВИ, Ковригина АМ, Насонов ЕЛ. IgG4-связанное системное заболевание. Современный взгляд на старые болезни. Научно-практическая ревматология. 2012;50(5):64-72 doi: 10.14412/1995-4484-2012-1184Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheum. 2014;66:740-9. doi: 10.1002/art.38270Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539-51. doi: 10.1056/NEJMra1104650Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181-92. doi: 10.1038/modpathol.2012.72Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460-71. doi: 10.1016/S0140-6736(14)60720-0Sedyshev SK, Vasiliev VI, Kovriguina AM, Nasonov EL. IgG4-linked systemic disease. Modern outlook on «old» disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(5):64-72 (In Russ.). doi: 10.14412/1995-4484-2012-1184Сокол ЕВ, Васильев ВИ. Лечение IgG4-связанного заболевания. Научно-практическая ревматология. 2016;54(3):352-60 doi: 10.14412/1995-4484-2016-352-360Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539-51. doi: 10.1056/NEJMra1104650Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352-8. doi: 10.1097/MPA.0b013e3182142fd2Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460-71. doi: 10.1016/S0140-6736(14)60720-0Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012;19(5):536-42. doi: 10.1007/s00534-012-0521-yСокол ЕВ, Васильев ВИ. Лечение IgG4-связанного заболевания. Научно-практическая ревматология. 2016;54(3):352-60 [Sokol EV, Vasilyev VI. Treatment of IgGrelated disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):352-60 (In Russ.)]. doi: 10.14412/1995-4484-2016-352-360Brito-Zeron P, Kostov B, Bosch X, et al. Therapeutic approach to IgG4-related disease: A systematic review. Medicine (Baltimore). 2016;95(26):e4002. doi: 10.1097/MD.0000000000004002Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352-8. doi: 10.1097/MPA.0b013e3182142fd2Della-Torre E, Lanzillotta M, Doglioni C. Immunology of IgG4-related disease. Clin Exp Immunol. 2015;181(2):191-206. doi: 10.1111/cei.12641Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012;19(5):536-42. doi: 10.1007/s00534-012-0521-yTopazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2008;6(3):364-6. doi: 10.1016/j.cgh.2007.12.020Brito-Zeron P, Kostov B, Bosch X, et al. Therapeutic approach to IgG4-related disease: A systematic review. Medicine (Baltimore). 2016;95(26):e4002. doi: 10.1097/MD.0000000000004002Васильев ВИ, Пальшина СГ, Симонова МВ и др. Первый опыт применения ритуксимаба в терапии болезни Микулича. Терапевтический архив. 2010;82(6):62-6Della-Torre E, Lanzillotta M, Doglioni C. Immunology of IgG4-related disease. Clin Exp Immunol. 2015;181(2):191-206. doi: 10.1111/cei.12641Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 2010;62(6):1755-62. doi: 10.1002/art.27435Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2008;6(3):364-6. doi: 10.1016/j.cgh.2007.12.020Седышев СХ, Васильев В.И. Ковригина ФМ и др. Заболевание, связанные с IgG4: характеристика группы больных и терапии ритуксимабом. Терапевтический архив. 2013;85(2):48-53Vasil'ev VI, Pal'shina SG, Simonova MV, et al. The first experience with rituximab in the treatment of Mikulich’s diseases. Terapevticheskiy Arkhiv. 2010;82(6):62-6 (In Russ.).McMahon BA, Novick T, Scheel PJ, et al. Rituximab for the Treatment of IgG4-Related Tubulointerstitial Nephritis: Case Report and Review of the Literature. Medicine (Baltimore). 2015;94(32):e1366. doi: 10.1097/MD.0000000000001366Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 2010;62(6):1755-62. doi: 10.1002/art.27435Zaidan M, Cervera-Pierot P, de Seigneux S, et al. Evidence of follicular T-cell implication in a case of IgG4-related systemic disease with interstitial nephritis. Nephrol Dial Transplant. 2011;26(6):2047-50. doi: 10.1093/ndt/gfr097Sedyshev SKh, Vasil'ev V.I. Kovrigina FM, et al. IgG4-related disease: characterization of the patient group and rituximab therapy. Terapevticheskiy Arkhiv. 2013;85(2):48-53 (In Russ.).Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012;91(1):57-66. doi: 10.1097/MD.0b013e3182431ef6McMahon BA, Novick T, Scheel PJ, et al. Rituximab for the Treatment of IgG4-Related Tubulointerstitial Nephritis: Case Report and Review of the Literature. Medicine (Baltimore). 2015;94(32):e1366. doi: 10.1097/MD.0000000000001366Wallace ZS, Mattoo H, Mahajan VS, et al. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford). 2016;55(6):1000. doi: 10.1093/rheumatology/kev438Zaidan M, Cervera-Pierot P, de Seigneux S, et al. Evidence of follicular T-cell implication in a case of IgG4-related systemic disease with interstitial nephritis. Nephrol Dial Transplant. 2011;26(6):2047-50. doi: 10.1093/ndt/gfr097Wu A, Andrew NH, Tsirbas A, et al. Rituximab for the treatment of IgG4-related orbital disease: experience from five cases. Eye (Lond). 2015;29(1):122. doi: 10.1038/eye.2014.251Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012;91(1):57-66. doi: 10.1097/MD.0b013e3182431ef6Yamamoto M, Awakawa T, Takahashi H. Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years. Ann Rheum Dis. 2015;74(8):e46 doi: 10.1136/annrheumdis-2015-207625Wallace ZS, Mattoo H, Mahajan VS, et al. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford). 2016;55(6):1000. doi: 10.1093/rheumatology/kev438Pomponio G, Olivari D, Mattioli M, et al. Sustained clinical response after single course of rituximab as first-line monotherapy in adult-onset asthma and periocular xanthogranulomas syndrome associated with IgG4-related disease: A case report. Medicine (Baltimore). 2018 Jun;97(26):e11143. doi: 10.1097/MD.00000000000Wu A, Andrew NH, Tsirbas A, et al. Rituximab for the treatment of IgG4-related orbital disease: experience from five cases. Eye (Lond). 2015;29(1):122. doi: 10.1038/eye.2014.251Quattrocchio G, Barreca A, Demarchi A, et al. IgG4-related kidney disease: the effects of a Rituximab-based immunosuppressive therapy. Oncotarget. 2018 Apr 20;9(30):21337-47. doi: 10.18632/oncotarget.25095Yamamoto M, Awakawa T, Takahashi H. Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years. Ann Rheum Dis. 2015;74(8):e46 doi: 10.1136/annrheumdis-2015-207625Gu WJ, Zhang Q, Zhu J, et al. Rituximab was used to treat recurrent IgG4-related hypophysitis with ophthalmopathy as the initial presentation: A case report and literature review. Medicine (Baltimore). 2017 Jun;96(24):e6934. doi: 10.1097/MD.0000000000006Pomponio G, Olivari D, Mattioli M, et al. Sustained clinical response after single course of rituximab as first-line monotherapy in adult-onset asthma and periocular xanthogranulomas syndrome associated with IgG4-related disease: A case report. Medicine (Baltimore). 2018 Jun;97(26):e11143. doi: 10.1097/MD.00000000000Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS One. 2017 Sep 15;12(9):e0183844. doi: 10.1371/journal.pone.0183844Quattrocchio G, Barreca A, Demarchi A, et al. IgG4-related kidney disease: the effects of a Rituximab-based immunosuppressive therapy. Oncotarget. 2018 Apr 20;9(30):21337-47. doi: 10.18632/oncotarget.25095Majumder S, Mohapatra S, Lennon RJ, et al. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease. Longterm efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. Clin Gastroenterol Hepatol. 2018 Dec;16(12):1947-53. doi: 10.1016/j.cgh.2018.0Gu WJ, Zhang Q, Zhu J, et al. Rituximab was used to treat recurrent IgG4-related hypophysitis with ophthalmopathy as the initial presentation: A case report and literature review. Medicine (Baltimore). 2017 Jun;96(24):e6934. doi: 10.1097/MD.0000000000006Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171-7. doi: 10.1136/annrheumdis-2014-206605Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS One. 2017 Sep 15;12(9):e0183844. doi: 10.1371/journal.pone.0183844Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13(4):217-33. doi: 10.1038/nrrheum.2017.22Majumder S, Mohapatra S, Lennon RJ, et al. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease. Longterm efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. Clin Gastroenterol Hepatol. 2018 Dec;16(12):1947-53. doi: 10.1016/j.cgh.2018.0Насонов ЕЛ, Решетняк ТМ, Денисов ЛН и др. Белимумаб: прогресс в лечении системной красной волчанки. Научно-практическая ревматология. 2012;50(5):13-9 doi: 10.14412/1995-4484-2012-1174Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171-7. doi: 10.1136/annrheumdis-2014-206605Samy E, Wax S, Huard B, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36(1):3-19. doi: 10.1080/08830185.2016.1276903Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13(4):217-33. doi: 10.1038/nrrheum.2017.22Ehrenstein MR,Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367-72. doi: 10.1038/nrrheum.2016.18Nasonov EL, Reshetnyak TM, Denisov LN, et al. Belimumab: advances in drug therapy for systemic lupus erythematosus. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(5):13-9 (In Russ.). doi: 10.14412/1995-4484-2012-1174Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328-37. doi: 10.1002/art.34400Samy E, Wax S, Huard B, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36(1):3-19. doi: 10.1080/08830185.2016.1276903Bekar KW, Owen T, Dunn R, et al. Prolonged effects of shortterm anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 2010;62:2443-57. doi: 10.1002/art.27515Ehrenstein MR,Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367-72. doi: 10.1038/nrrheum.2016.18Lin W, Seshasayee D, Lee WP, et al. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheum. 2015;67:215-24. doi: 10.1002/art.38907Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328-37. doi: 10.1002/art.34400Carter LM, Isenberg DA. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 2013;65(10):2672-9. doi: 10.1002/art.38074Bekar KW, Owen T, Dunn R, et al. Prolonged effects of shortterm anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 2010;62:2443-57. doi: 10.1002/art.27515Kraaij T, Huizinga TW, Rabelink TJ, et al. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology. 2014;53:2122-4. doi: 10.1093/rheumatology/keu369Lin W, Seshasayee D, Lee WP, et al. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheum. 2015;67:215-24. doi: 10.1002/art.38907Simonetta F, Allali D, Roux-Lombard P, et al. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine. 2017;84(2):235-6. doi: 10.1016/j.jbspin.2016.01.008Carter LM, Isenberg DA. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 2013;65(10):2672-9. doi: 10.1002/art.38074Gonzalez-Echavarri C, Ugarte A, Ruiz-Irastorza G. Rituximabrefractory lupus nephritis successfully treated with belimumab. Clin Exp Rheumatol. 2016;34:355-56.Kraaij T, Huizinga TW, Rabelink TJ, et al. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology. 2014;53:2122-4. doi: 10.1093/rheumatology/keu369De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by rituximab in Sjö gren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol. 2014;32:490-4.Simonetta F, Allali D, Roux-Lombard P, et al. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine. 2017;84(2):235-6. doi: 10.1016/j.jbspin.2016.01.008Gualtierotti R, Borghi MO, Gerosa M, et al. Successful sequential therapy with rituximab and belimumab in patients with active systemiclupus erythematosus: a case series. Clin Exp Rheumatol. 2018 Feb 27.Gonzalez-Echavarri C, Ugarte A, Ruiz-Irastorza G. Rituximabrefractory lupus nephritis successfully treated with belimumab. Clin Exp Rheumatol. 2016;34:355-56.Kraaij T, Kamerling SWA, de Rooij ENM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018;91:45-54. doi: 10.1016/j.jaut.2018.03.003De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by rituximab in Sjö gren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol. 2014;32:490-4.Aranow C, Dall'Era M, Byron M, et al., on behalf of the CALIBRATE investigators and Lupus Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis [abstract]. Ann Rheum Dis. 2018;77:A690. doi: 10.1136/annrheumdis-2018-eular.5711Gualtierotti R, Borghi MO, Gerosa M, et al. Successful sequential therapy with rituximab and belimumab in patients with active systemiclupus erythematosus: a case series. Clin Exp Rheumatol. 2018 Feb 27.Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526-31. doi: 10.1136/annrheumdis-2013-203991Kraaij T, Kamerling SWA, de Rooij ENM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018;91:45-54. doi: 10.1016/j.jaut.2018.03.003Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue diseaseassociated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18(1):275. doi: 10.1186/s13063-017-2016-2Aranow C, Dall'Era M, Byron M, et al., on behalf of the CALIBRATE investigators and Lupus Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis [abstract]. Ann Rheum Dis. 2018;77:A690. doi: 10.1136/annrheumdis-2018-eular.5711ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03312907Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526-31. doi: 10.1136/annrheumdis-2013-203991BEAT Lupus. https://beatlupus.uk/ (2017).Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue diseaseassociated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18(1):275.ClinicalTrials.gov. NCT03054259doi: 10.1186/s13063-017-2016-2ClinicalTrials.gov. number NCT01773616ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03312907ClinicalTrials.gov. Identifier: NCT01748084BEAT Lupus. https://beatlupus.uk/ (2017).ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02631538ClinicalTrials.gov. NCT03054259ClinicalTrials.gov. Identifier: NCT02990286ClinicalTrials.gov. number NCT01773616Меснянкина АА, Соловьев СК, Александрова ЕН и др. Двойная терапия генно-инженерными биологическими препаратами у пациентов с системной красной волчанкой. Научно-практическая ревматология. 2016;54(3):281-8 doi: 10.14412/1995-4484-2016-281-288ClinicalTrials.gov. Identifier: NCT01748084Меснянкина АА, Соловьев СК, Асеева ЕА, Насонов ЕЛ. Эффективность генно-инженерной биологической терапии и особенности гуморального иммунитета у больных системной красной волчанкой. Научно-практическая ревматология. 2018;56(3):302-9 doi: 10.14412/1995-4484-2018-302-309ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02631538Бекетова ТВ, Волков МЮ, Никонорова НО, Новоселова ТМ. Опыт эффективного применения комбинированной анти-В-клеточной терапии ритуксимабом и белимумабом при рефрактерном гранулематозе с полиангиитом (Вегенера) с тяжелым поражением легких. Научно-практическая ревматология. 2017;55(1):104-9 doi: 10.14412/1995-4484-2017-104-109ClinicalTrials.gov. Identifier: NCT02990286Roberts DM, Jones RB, Smith RM, et al. Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60-5. doi: 10.1016/j.jaut.2014.11.009Mesnyankina AA, Solovyev SK, Aleksandrova EN, et al. Dual therapy with biologicals in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):281-8 (In Russ.). doi: 10.14412/1995-4484-2016-281-288Kaplan B, Kopyltsova Y, Khokhar A, et al. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract. 2014;2:594-600. doi: 10.1016/j.jaip.2014.06.003Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):302-9 (In Russ.). doi: 10.14412/1995-4484-2018-302-309Kobelt G, Kasteng F. Access to Innovative Treatments in Rheumatoid Arthritis in Europe. 2009. Available at: http://www.comparatorreports.se/Access to MS treatments - October 2009.pdfBeketova TV, Volkov MYu, Nikonorova NO, Novoselova TM. Experience with effective combined anti-Bcell therapy with rituximab and belimumab for refractory granulomatosis with polyangiitis (Wegener's) with severe lung damage. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(1):104-9 (In Russ.). doi: 10.14412/1995-4484-2017-104-109Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? Front Pharmacol. 2019 Mar 28;10:279. doi: 10.3389/fphar.2019.00279Roberts DM, Jones RB, Smith RM, et al. Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60-5. doi: 10.1016/j.jaut.2014.11.009Dö rner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75:974-82. doi: 10.1136/annrheumdis-2016-209166Kaplan B, Kopyltsova Y, Khokhar A, et al. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract. 2014;2:594-600. doi: 10.1016/j.jaip.2014.06.003Kay J, Schoels MM, Dö rner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77:165-74. doi: 10.1136/annrheumdis-2017-211937Kaplan B, Kopyltsova Y, Khokhar A, et al. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract. 2014;2:594-600. doi: 10.1016/j.jaip.2014.06.003Smolen JS, Goncalves J, Quinn M, et al. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019 May 21;5(1):e000900. doi: 10.1136/rmdopen-2019-000900Kobelt G, Kasteng F. Access to Innovative Treatments in Rheumatoid Arthritis in Europe. 2009. Available at: http://www.comparatorreports.se/Access to MS treatments - October 2009.pdfНасонов ЕЛ. Биоаналоги в ревматологии. Научно-практическая ревматология. 2016;54(6):628-40 doi: 10.14412/1995-4484-2016-628-640Kobelt G, Kasteng F. Access to Innovative Treatments in Rheumatoid Arthritis in Europe. 2009. Available at: http://www.comparatorreports.se/Access to MS treatments - October 2009.pdfGreenwald M, Tesser J, Sewell KL. Biosimilars have arrived: Rituximab. Arthritis. 2018;2018:3762864. doi: 10.1155/2018/3762864. eCollection 2018.Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? Front Pharmacol. 2019 Mar 28;10:279. doi: 10.3389/fphar.2019.00279Yoo DH, Suh CH, Shim SC, et al. A multicentre randomized controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:566-70. doi: 10.1136/annrheumdis-2016-209540Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? Front Pharmacol. 2019 Mar 28;10:279. doi: 10.3389/fphar.2019.00279Park W, Bozic-Majstorovic L, Milakovic D, et al. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. MAbs. 2018;10(6):934-43. doi: 10.1080/19420862.2018.1487912Dö rner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75:974-82. doi: 10.1136/annrheumdis-2016-209166Cohen SB, Burgos-Vargas R, Emery P, et al. An extension study of PF-05280586, a potential Rituximab biosimilar, versus Rituximab in subjects with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018 Apr 25. doi: 10.1002/acr.23586Dö rner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75:974-82. doi: 10.1136/annrheumdis-2016-209166Насонов ЕЛ, Мазуров ВИ, Усачева ЮВ и др. Разработки отечественных оригинальных генно-инженерных биологических препаратов для лечения иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2017;55(2):201-10 doi: 10.14412/1995-4484-2017-201-210Kay J, Schoels MM, Dö rner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77:165-74. doi: 10.1136/annrheumdis-2017-211937Насонов ЕЛ, Зонова ЕВ, Иванова ОН и др. Результаты сравнительного клинического исследования III фазы препаратов ритуксимаба (Ацеллбия® и Мабтера®) при ревматоидном артрите (исследование BIORA). Научно-практическая ревматология. 2016;54(5):510-9 doi: 10.14412/1995-4484-2016-510-519Kay J, Schoels MM, Dö rner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77:165-74. doi: 10.1136/annrheumdis-2017-211937Насонов ЕЛ, Мазуров ВИ, Зонова ЕВ и др. Эффективность и безопасность биоаналога ритуксимаба (Ацеллбия®) при ревматоидном артрите в качестве «первого» генноинженерного биологического препарата: результаты клинического исследования III фазы (ALTERRA). Научно-практическая ревматология.2017;55(4):351-9 doi: 10.14412/1995-4484-2017-351-359Smolen JS, Goncalves J, Quinn M, et al. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019 May 21;5(1):e000900. doi: 10.1136/rmdopen-2019-000900Bredemeier M, de Oliveira FK, Rocha CM. Low-versus Highdose rituximab for rheumatoid arthritis: a systemic review and meta-analysis. Arthritis Care Res. 2014;66:228-35. doi: 10.1002/acr.22116Smolen JS, Goncalves J, Quinn M, et al. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019 May 21;5(1):e000900. doi: 10.1136/rmdopen-2019-000900Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-20. doi: 10.1136/ard.2010.144998Nasonov EL. Biosimilars in rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(6):628-40 (In Russ.). doi: 10.14412/1995-4484-2016-628-640Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-400. doi: 10.1002/art.21778Nasonov EL. Biosimilars in rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(6):628-40 (In Russ.). doi: 10.14412/1995-4484-2016-628-640Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab. Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. J Rheumatol. 2008;35:20-30.Greenwald M, Tesser J, Sewell KL. Biosimilars have arrived: Rituximab. Arthritis. 2018;2018:3762864. doi: 10.1155/2018/3762864. eCollection 2018.Mease P, Szechinski J, Greenwald M, et al. Improvements in patient reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in phase IIb trial (DANCER) [abstract]. Arthritis Rheum. 2005;52 Suppl:S138-9.Greenwald M, Tesser J, Sewell KL. Biosimilars have arrived: Rituximab. Arthritis. 2018;2018:3762864. doi: 10.1155/2018/3762864. eCollection 2018.Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX inadequate responders (SERENE)). Ann Rheum Dis. 2010;69:1629-35. doi: 10.1136/ard.2009.119933Yoo DH, Suh CH, Shim SC, et al. A multicentre randomized controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:566-70. doi: 10.1136/annrheumdis-2016-209540Deodhar A, Isaacs J, Rigby W, et al. Improved quality of life (QoL) with rituximab (RTX) as first-line biologic therapy in patients (pts) with active rheumatoid arthritis (RA): results from a phase III randomized controlled study (SERENE) [abstract]. Arthritis Rheum. 2008;58 Suppl:S302.Yoo DH, Suh CH, Shim SC, et al. A multicentre randomized controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:566-70. doi: 10.1136/annrheumdis-2016-209540Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint dam- age and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46. doi: 10.1136/ard.2010.137703Park W, Bozic-Majstorovic L, Milakovic D, et al. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. MAbs. 2018;10(6):934-43. doi: 10.1080/19420862.2018.1487912Tak PP, Rigby W, Rubbert A, et al. Rituximab plus methotrexate (MTX) inhibits joint damage and improves clinical outcomes in patients with early, active rheumatoid arthritis (RA) who are naive to MTX [abstract]. Rheumatology (Oxford). 2010;49:i4.Park W, Bozic-Majstorovic L, Milakovic D, et al. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. MAbs. 2018;10(6):934-43. doi: 10.1080/19420862.2018.1487912Rigby W, Ferraccioli G, Greenwald M, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken). 2011;63:711-20. doi: 10.1002/acr.20419Cohen SB, Burgos-Vargas R, Emery P, et al. An extension study of PF-05280586, a potential Rituximab biosimilar, versus Rituximab in subjects with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018 Apr 25. doi: 10.1002/acr.23586Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71:351-7. doi: 10.1136/annrheumdis-2011-200170Cohen SB, Burgos-Vargas R, Emery P, et al. An extension study of PF-05280586, a potential Rituximab biosimilar, versus Rituximab in subjects with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018 Apr 25. doi: 10.1002/acr.23586Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683-93. doi: 10.1093/rheumatology/keq116Nasonov EL, Mazurov VI, Usacheva YuV, et al. Developments of Russian original biological agents for the treatment of immunoinflammatory rheumatic diseases. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):201-10 (In Russ.). doi: 10.14412/1995-4484-2017-201-210Peterfy C, Emery P, Tak PP, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis. 2016;75(1):170-7. doi: 10.1136/annrheumdis-2014-206015Nasonov EL, Mazurov VI, Usacheva YuV, et al. Developments of Russian original biological agents for the treatment of immunoinflammatory rheumatic diseases. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):201-10 (In Russ.). doi: 10.14412/1995-4484-2017-201-210Welsing PM, Borm GF, van Riel P. Minimal clinically important difference in radiological progression of joint damage: a definition based on patient perspective. J Rheumatol. 2006;33:501-7.Nasonov EL, Zonova EV, Ivanova ON, et al. The results of a phase III comparative clinical trial of rituximab (Acellbia® and MabThera®) in rheumatoid arthritis (the BIORA study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):510-9 (In Russ.). doi: 10.14412/1995-4484-2016-510-519Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1114-21. doi: 10.1093/rheumatology/kep155Nasonov EL, Zonova EV, Ivanova ON, et al. The results of a phase III comparative clinical trial of rituximab (Acellbia® and MabThera®) in rheumatoid arthritis (the BIORA study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):510-9 (In Russ.). doi: 10.14412/1995-4484-2016-510-519Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73(8):1508-14. doi: 10.1136/annrheumdis-2013-203480Nasonov EL, Mazurov VI, Zonova EV, et al. The efficacy and safety of rituximab biosimilar (Acellbia®) in rheumatoid arthritis as the first biological agent: Results of Phase III (ALTERRA) clinical trial. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):351-9 (In Russ.). doi: 10.14412/1995-4484-2017-351-359Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50. doi: 10.1186/s13075-016-0951-zNasonov EL, Mazurov VI, Zonova EV, et al. The efficacy and safety of rituximab biosimilar (Acellbia®) in rheumatoid arthritis as the first biological agent: Results of Phase III (ALTERRA) clinical trial. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):351-9 (In Russ.). doi: 10.14412/1995-4484-2017-351-359Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603-8. doi: 10.1002/art.30152Bredemeier M, de Oliveira FK, Rocha CM. Low-versus Highdose rituximab for rheumatoid arthritis: a systemic review and meta-analysis. Arthritis Care Res. 2014;66:228-35. doi: 10.1002/acr.22116McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865-7. doi: 10.1093/rheumatology/ken103Bredemeier M, de Oliveira FK, Rocha CM. Low-versus Highdose rituximab for rheumatoid arthritis: a systemic review and meta-analysis. Arthritis Care Res. 2014;66:228-35. doi: 10.1002/acr.22116Reddy V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune disease: an opportunity for personalized therapy? Int J Clin Rheumatol. 2014;9(3):279-93. doi: 10.2217/ijr.14.18Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-20. doi: 10.1136/ard.2010.144998Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-14. doi: 10.1002/art.30427Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-20. doi: 10.1136/ard.2010.144998Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-сenter study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012;79:365-9. doi: 10.1016/j.jbspin.2011.12.004Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-400. doi: 10.1002/art.21778Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venerol. 2017;83(3):317-25. doi: 10.4103/ijdvl.IJDVL_1078_14Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-400. doi: 10.1002/art.21778Robinson AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and singlecentre long-term review of nine patients. Australas J Dermatol. 2017 Feb 17. doi: 10.1111/ajd.12571Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab. Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. J Rheumatol. 2008;35:20-30.Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant. 2016 Jul 6. doi: 10.1093/ndt/gfw251Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab. Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. J Rheumatol. 2008;35:20-30.Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546-51. doi: 10.1111/ejh.12199Mease P, Szechinski J, Greenwald M, et al. Improvements in patient reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in phase IIb trial (DANCER) [abstract]. Arthritis Rheum. 2005;52 Suppl:S138-9.Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494-500. doi: 10.1111/ejh.12102Mease P, Szechinski J, Greenwald M, et al. Improvements in patient reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in phase IIb trial (DANCER) [abstract]. Arthritis Rheum. 2005;52 Suppl:S138-9.Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi: 10.1093/rheumatology/ker176Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX inadequate responders (SERENE)). Ann Rheum Dis. 2010;69:1629-35. doi: 10.1136/ard.2009.119933Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX inadequate responders (SERENE)). Ann Rheum Dis. 2010;69:1629-35. doi: 10.1136/ard.2009.119933Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi: 10.1002/art.23059Deodhar A, Isaacs J, Rigby W, et al. Improved quality of life (QoL) with rituximab (RTX) as first-line biologic therapy in patients (pts) with active rheumatoid arthritis (RA): results from a phase III randomized controlled study (SERENE) [abstract]. Arthritis Rheum. 2008;58 Suppl:S302.Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi: 10.1136/ard.2009.109041Deodhar A, Isaacs J, Rigby W, et al. Improved quality of life (QoL) with rituximab (RTX) as first-line biologic therapy in patients (pts) with active rheumatoid arthritis (RA): results from a phase III randomized controlled study (SERENE) [abstract]. Arthritis Rheum. 2008;58 Suppl:S302.Авдеева АС, Сатыбалдыев АМ, Демидова НВ и др. Оценка терапии ритуксимабом в реальной клинической практике (по данным регистра больных ревматоидным артритом ОРЕЛ). Научно-практическая ревматология. 2019;57(3):274-9 doi: 10.14412/1995-4484-2019-274-279Deodhar A, Isaacs J, Rigby W, et al. Improved quality of life (QoL) with rituximab (RTX) as first-line biologic therapy in patients (pts) with active rheumatoid arthritis (RA): results from a phase III randomized controlled study (SERENE) [abstract]. Arthritis Rheum. 2008;58 Suppl:S302.Насонов ЕЛ, Каратеев ДЕ, Сатыбалдыев АМ и др. Ревматоидный артрит в Российской Федерации по данным Российского регистра больных артритом (сообщение I). Научно-практическая ревматология. 2015;53(5):472-84 doi: 10.14412/1995-4484-2015-472-484Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint dam- age and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46. doi: 10.1136/ard.2010.137703Bae SC, Lee YH. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis. Int J Clin Pharmacol Ther. 2019 57(4):188-96. doi: 10.5414/CP203360Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint dam- age and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46. doi: 10.1136/ard.2010.137703Tony HP, Krü ger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference Rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88-94. doi: 10.1002/acr.23771Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint dam- age and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46. doi: 10.1136/ard.2010.137703Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003Tak PP, Rigby W, Rubbert A, et al. Rituximab plus methotrexate (MTX) inhibits joint damage and improves clinical outcomes in patients with early, active rheumatoid arthritis (RA) who are naive to MTX [abstract]. Rheumatology (Oxford). 2010;49:i4.Jog NR, James J. Biomarkers in connective tissue diseases. A. J Allergy Clin Immunol. 2017;140(6):1473-83. doi: 10.1016/j.jaci.2017.10.003Tak PP, Rigby W, Rubbert A, et al. Rituximab plus methotrexate (MTX) inhibits joint damage and improves clinical outcomes in patients with early, active rheumatoid arthritis (RA) who are naive to MTX [abstract]. Rheumatology (Oxford). 2010;49:i4.Александрова ЕН, Новиков АА, Насонов ЕЛ. Современные подходы к лабораторной диагностике ревматических заболеваний: роль молекулярных и клеточных биомаркеров. Научно-практическая ревматология. 2016;54(3):324-38 doi: 10.14412/1995-4484-2016-324-338Tak PP, Rigby W, Rubbert A, et al. Rituximab plus methotrexate (MTX) inhibits joint damage and improves clinical outcomes in patients with early, active rheumatoid arthritis (RA) who are naive to MTX [abstract]. Rheumatology (Oxford). 2010;49:i4.Авдеева АС, Артюхов АС, Дашинимаев ЭБ и др. Динамика показателей цитокинового профиля на фоне применения биоаналога ритуксимаба (Ацеллбия, «БИОКАД») и оригинального препарата (Мабтера, «Ф. Хоффманн-Ля Рош» Лтд., Швейцария) в терапии ревматоидного артрита. Научно-практическая ревматология. 2019;57(1):46-55 doi: 10.14412/1995-4484-2019-46-55Rigby W, Ferraccioli G, Greenwald M, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken). 2011;63:711-20. doi: 10.1002/acr.20419Авдеева АС, Черкасова МВ, Кусевич ДА и др. Иммунологические эффекты биоаналога ритуксимаба (Ацеллбия, «БИОКАД») у больных ревматоидным артритом. Научно-практическая ревматология. 2018;56(5):556-63 doi: 10.14412/1995-4484-2018-556-563Rigby W, Ferraccioli G, Greenwald M, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken). 2011;63:711-20. doi: 10.1002/acr.20419Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8:515-9. doi: 10.1016/j.autrev.2009.01.007Rigby W, Ferraccioli G, Greenwald M, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken). 2011;63:711-20. doi: 10.1002/acr.20419Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196.Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71:351-7. doi: 10.1136/annrheumdis-2011-200170Александрова ЕН, Авдеева АС, Лукина ГВ и др. Клинико-иммунологические эффекты анти-В-клеточной терапии у больных ревматоидным артритом. Научно-практическая ревматология. 2012;50(1):14-21 doi: 10.14412/1995-4484-2012-498Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71:351-7. doi: 10.1136/annrheumdis-2011-200170Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723-32. doi: 10.1002/art.21650Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71:351-7. doi: 10.1136/annrheumdis-2011-200170Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. doi: 10.1002/art.22025Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683-93. doi: 10.1093/rheumatology/keq116Higashida J, Wun T, Schmidt S. Safety and efficacy of Rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683-93. doi: 10.1093/rheumatology/keq116Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets Ther. 2008;2:911-6. doi: 10.2147/BTT.S3939Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683-93. doi: 10.1093/rheumatology/keq116Bokareva M, Lindholm C, Zendjanchi K, et al. Efficacy of antiCD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. doi: 10.1111/j.1365-3083.2007.01995.xPeterfy C, Emery P, Tak PP, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis. 2016;75(1):170-7. doi: 10.1136/annrheumdis-2014-206015Toubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20. doi: 10.1136/ard.2006.062505Peterfy C, Emery P, Tak PP, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis. 2016;75(1):170-7. doi: 10.1136/annrheumdis-2014-206015Vizioli C, Viana V, Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:667. doi: 10.1136/annrheumdis-2012-eular.519Peterfy C, Emery P, Tak PP, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis. 2016;75(1):170-7. doi: 10.1136/annrheumdis-2014-206015Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009. doi: 10.1136/rmdopen-2014-000009Welsing PM, Borm GF, van Riel P. Minimal clinically important difference in radiological progression of joint damage: a definition based on patient perspective. J Rheumatol. 2006;33:501-7.Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150Welsing PM, Borm GF, van Riel P. Minimal clinically important difference in radiological progression of joint damage: a definition based on patient perspective. J Rheumatol. 2006;33:501-7.Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133Welsing PM, Borm GF, van Riel P. Minimal clinically important difference in radiological progression of joint damage: a definition based on patient perspective. J Rheumatol. 2006;33:501-7.Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjö gren's Syndrome. Rheumatology (Oxford). 2017 1;56(10):e24-e48. doi: 10.1093/rheumatology/kex166Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1114-21. doi: 10.1093/rheumatology/kep155Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-28. doi: 10.1016/S1474-4422(18)30254-0Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1114-21. doi: 10.1093/rheumatology/kep155Clinical Commissioning Policy: Rituximab for the treatment of dermatomyositis and polymyositis. NHS England 16036/P, 2017.Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1114-21. doi: 10.1093/rheumatology/kep155Fernandez-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algoritm Group. Treatment Algoritm for Systemic Sclerosis According to Expert. Arthritis Rheum. 2018;70:1820-8. doi: 10.1002/art.40560Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73(8):1508-14. doi: 10.1136/annrheumdis-2013-203480Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73(8):1508-14. doi: 10.1136/annrheumdis-2013-203480Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73(8):1508-14. doi: 10.1136/annrheumdis-2013-203480Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73(8):1508-14. doi: 10.1136/annrheumdis-2013-203480Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73(8):1508-14. doi: 10.1136/annrheumdis-2013-203480Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50. doi: 10.1186/s13075-016-0951-zChatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50. doi: 10.1186/s13075-016-0951-zChatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50. doi: 10.1186/s13075-016-0951-zChatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50. doi: 10.1186/s13075-016-0951-zChatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50. doi: 10.1186/s13075-016-0951-zChatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50. doi: 10.1186/s13075-016-0951-zVital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603-8. doi: 10.1002/art.30152Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603-8. doi: 10.1002/art.30152Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603-8. doi: 10.1002/art.30152Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603-8. doi: 10.1002/art.30152Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603-8. doi: 10.1002/art.30152Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603-8. doi: 10.1002/art.30152McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865-7. doi: 10.1093/rheumatology/ken103McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865-7. doi: 10.1093/rheumatology/ken103McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865-7. doi: 10.1093/rheumatology/ken103McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865-7. doi: 10.1093/rheumatology/ken103McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865-7. doi: 10.1093/rheumatology/ken103McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865-7. doi: 10.1093/rheumatology/ken103Reddy V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune disease: an opportunity for personalized therapy? Int J Clin Rheumatol. 2014;9(3):279-93. doi: 10.2217/ijr.14.18Reddy V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune disease: an opportunity for personalized therapy? Int J Clin Rheumatol. 2014;9(3):279-93. doi: 10.2217/ijr.14.18Reddy V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune disease: an opportunity for personalized therapy? Int J Clin Rheumatol. 2014;9(3):279-93. doi: 10.2217/ijr.14.18Reddy V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune disease: an opportunity for personalized therapy? Int J Clin Rheumatol. 2014;9(3):279-93. doi: 10.2217/ijr.14.18Reddy V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune disease: an opportunity for personalized therapy? Int J Clin Rheumatol. 2014;9(3):279-93. doi: 10.2217/ijr.14.18Reddy V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune disease: an opportunity for personalized therapy? Int J Clin Rheumatol. 2014;9(3):279-93. doi: 10.2217/ijr.14.18Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-14. doi: 10.1002/art.30427Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-14. doi: 10.1002/art.30427Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-14. doi: 10.1002/art.30427Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-14. doi: 10.1002/art.30427Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-14. doi: 10.1002/art.30427Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-14. doi: 10.1002/art.30427Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-сenter study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012;79:365-9. doi: 10.1016/j.jbspin.2011.12.004Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-сenter study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012;79:365-9. doi: 10.1016/j.jbspin.2011.12.004Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-сenter study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012;79:365-9. doi: 10.1016/j.jbspin.2011.12.004Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-сenter study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012;79:365-9. doi: 10.1016/j.jbspin.2011.12.004Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-сenter study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012;79:365-9. doi: 10.1016/j.jbspin.2011.12.004Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-сenter study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012;79:365-9. doi: 10.1016/j.jbspin.2011.12.004Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venerol. 2017;83(3):317-25. doi: 10.4103/ijdvl.IJDVL_1078_14Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venerol. 2017;83(3):317-25. doi: 10.4103/ijdvl.IJDVL_1078_14Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venerol. 2017;83(3):317-25. doi: 10.4103/ijdvl.IJDVL_1078_14Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venerol. 2017;83(3):317-25. doi: 10.4103/ijdvl.IJDVL_1078_14Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venerol. 2017;83(3):317-25. doi: 10.4103/ijdvl.IJDVL_1078_14Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venerol. 2017;83(3):317-25. doi: 10.4103/ijdvl.IJDVL_1078_14Robinson AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and singlecentre long-term review of nine patients. Australas J Dermatol. 2017 Feb 17. doi: 10.1111/ajd.12571Robinson AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and singlecentre long-term review of nine patients. Australas J Dermatol. 2017 Feb 17. doi: 10.1111/ajd.12571Robinson AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and singlecentre long-term review of nine patients. Australas J Dermatol. 2017 Feb 17. doi: 10.1111/ajd.12571Robinson AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and singlecentre long-term review of nine patients. Australas J Dermatol. 2017 Feb 17. doi: 10.1111/ajd.12571Robinson AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and singlecentre long-term review of nine patients. Australas J Dermatol. 2017 Feb 17. doi: 10.1111/ajd.12571Robinson AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and singlecentre long-term review of nine patients. Australas J Dermatol. 2017 Feb 17. doi: 10.1111/ajd.12571Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant. 2016 Jul 6. doi: 10.1093/ndt/gfw251Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant. 2016 Jul 6. doi: 10.1093/ndt/gfw251Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant. 2016 Jul 6. doi: 10.1093/ndt/gfw251Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant. 2016 Jul 6. doi: 10.1093/ndt/gfw251Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant. 2016 Jul 6. doi: 10.1093/ndt/gfw251Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant. 2016 Jul 6. doi: 10.1093/ndt/gfw251Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546-51. doi: 10.1111/ejh.12199Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546-51. doi: 10.1111/ejh.12199Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546-51. doi: 10.1111/ejh.12199Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546-51. doi: 10.1111/ejh.12199Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546-51. doi: 10.1111/ejh.12199Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546-51. doi: 10.1111/ejh.12199Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494-500. doi: 10.1111/ejh.12102Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494-500. doi: 10.1111/ejh.12102Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494-500. doi: 10.1111/ejh.12102Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494-500. doi: 10.1111/ejh.12102Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494-500. doi: 10.1111/ejh.12102Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494-500. doi: 10.1111/ejh.12102Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi: 10.1093/rheumatology/ker176Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi: 10.1093/rheumatology/ker176Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi: 10.1093/rheumatology/ker176Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi: 10.1093/rheumatology/ker176Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi: 10.1093/rheumatology/ker176Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi: 10.1093/rheumatology/ker176Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi: 10.1093/rheumatology/ker176Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi: 10.1093/rheumatology/ker176Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi: 10.1002/art.23059Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi: 10.1002/art.23059Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi: 10.1002/art.23059Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi: 10.1002/art.23059Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi: 10.1002/art.23059Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi: 10.1002/art.23059Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi: 10.1002/art.23059Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi: 10.1002/art.23059Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi: 10.1136/ard.2009.109041Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi: 10.1136/ard.2009.109041Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi: 10.1136/ard.2009.109041Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi: 10.1136/ard.2009.109041Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi: 10.1136/ard.2009.109041Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi: 10.1136/ard.2009.109041Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi: 10.1136/ard.2009.109041Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi: 10.1136/ard.2009.109041Avdeeva AS, Satybaldyev AM, Demidova NV, et al. Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):274-9 (In Russ.). doi: 10.14412/1995-4484-2019-274-279Avdeeva AS, Satybaldyev AM, Demidova NV, et al. Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):274-9 (In Russ.). doi: 10.14412/1995-4484-2019-274-279Avdeeva AS, Satybaldyev AM, Demidova NV, et al. Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):274-9 (In Russ.). doi: 10.14412/1995-4484-2019-274-279Avdeeva AS, Satybaldyev AM, Demidova NV, et al. Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):274-9 (In Russ.). doi: 10.14412/1995-4484-2019-274-279Avdeeva AS, Satybaldyev AM, Demidova NV, et al. Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):274-9 (In Russ.). doi: 10.14412/1995-4484-2019-274-279Avdeeva AS, Satybaldyev AM, Demidova NV, et al. Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):274-9 (In Russ.). doi: 10.14412/1995-4484-2019-274-279Avdeeva AS, Satybaldyev AM, Demidova NV, et al. Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):274-9 (In Russ.). doi: 10.14412/1995-4484-2019-274-279Avdeeva AS, Satybaldyev AM, Demidova NV, et al. Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):274-9 (In Russ.). doi: 10.14412/1995-4484-2019-274-279Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.). doi: 10.14412/1995-4484-2015-472-484Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.). doi: 10.14412/1995-4484-2015-472-484Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.). doi: 10.14412/1995-4484-2015-472-484Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.). doi: 10.14412/1995-4484-2015-472-484Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.). doi: 10.14412/1995-4484-2015-472-484Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.). doi: 10.14412/1995-4484-2015-472-484Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.). doi: 10.14412/1995-4484-2015-472-484Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.). doi: 10.14412/1995-4484-2015-472-484Bae SC, Lee YH. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis. Int J Clin Pharmacol Ther. 2019 57(4):188-96. doi: 10.5414/CP203360Bae SC, Lee YH. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis. Int J Clin Pharmacol Ther. 2019 57(4):188-96. doi: 10.5414/CP203360Bae SC, Lee YH. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis. Int J Clin Pharmacol Ther. 2019 57(4):188-96. doi: 10.5414/CP203360Bae SC, Lee YH. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis. Int J Clin Pharmacol Ther. 2019 57(4):188-96. doi: 10.5414/CP203360Bae SC, Lee YH. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis. Int J Clin Pharmacol Ther. 2019 57(4):188-96. doi: 10.5414/CP203360Bae SC, Lee YH. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis. Int J Clin Pharmacol Ther. 2019 57(4):188-96. doi: 10.5414/CP203360Bae SC, Lee YH. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis. Int J Clin Pharmacol Ther. 2019 57(4):188-96. doi: 10.5414/CP203360Bae SC, Lee YH. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis. Int J Clin Pharmacol Ther. 2019 57(4):188-96. doi: 10.5414/CP203360Tony HP, Krü ger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference Rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88-94. doi: 10.1002/acr.23771Tony HP, Krü ger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference Rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88-94. doi: 10.1002/acr.23771Tony HP, Krü ger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference Rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88-94. doi: 10.1002/acr.23771Tony HP, Krü ger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference Rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88-94. doi: 10.1002/acr.23771Tony HP, Krü ger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference Rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88-94. doi: 10.1002/acr.23771Tony HP, Krü ger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference Rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88-94. doi: 10.1002/acr.23771Tony HP, Krü ger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference Rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88-94. doi: 10.1002/acr.23771Tony HP, Krü ger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference Rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88-94. doi: 10.1002/acr.23771Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003Jog NR, James J. Biomarkers in connective tissue diseases. A. J Allergy Clin Immunol. 2017;140(6):1473-83. doi: 10.1016/j.jaci.2017.10.003Jog NR, James J. Biomarkers in connective tissue diseases. A. J Allergy Clin Immunol. 2017;140(6):1473-83. doi: 10.1016/j.jaci.2017.10.003Jog NR, James J. Biomarkers in connective tissue diseases. A. J Allergy Clin Immunol. 2017;140(6):1473-83. doi: 10.1016/j.jaci.2017.10.003Jog NR, James J. Biomarkers in connective tissue diseases. A. J Allergy Clin Immunol. 2017;140(6):1473-83. doi: 10.1016/j.jaci.2017.10.003Jog NR, James J. Biomarkers in connective tissue diseases. A. J Allergy Clin Immunol. 2017;140(6):1473-83. doi: 10.1016/j.jaci.2017.10.003Jog NR, James J. Biomarkers in connective tissue diseases. A. J Allergy Clin Immunol. 2017;140(6):1473-83. doi: 10.1016/j.jaci.2017.10.003Jog NR, James J. Biomarkers in connective tissue diseases. A. J Allergy Clin Immunol. 2017;140(6):1473-83. doi: 10.1016/j.jaci.2017.10.003Jog NR, James J. Biomarkers in connective tissue diseases. A. J Allergy Clin Immunol. 2017;140(6):1473-83. doi: 10.1016/j.jaci.2017.10.003Aleksandrova EN, Novikov AA, Nasonov EL. Current approaches to the laboratory diagnosis of rheumatic diseases: Role of molecular and cellular biomarkers. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):324-38 (In Russ.). doi: 10.14412/1995-4484-2016-324-338Aleksandrova EN, Novikov AA, Nasonov EL. Current approaches to the laboratory diagnosis of rheumatic diseases: Role of molecular and cellular biomarkers. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):324-38 (In Russ.). doi: 10.14412/1995-4484-2016-324-338Aleksandrova EN, Novikov AA, Nasonov EL. Current approaches to the laboratory diagnosis of rheumatic diseases: Role of molecular and cellular biomarkers. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):324-38 (In Russ.). doi: 10.14412/1995-4484-2016-324-338Aleksandrova EN, Novikov AA, Nasonov EL. Current approaches to the laboratory diagnosis of rheumatic diseases: Role of molecular and cellular biomarkers. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):324-38 (In Russ.). doi: 10.14412/1995-4484-2016-324-338Aleksandrova EN, Novikov AA, Nasonov EL. Current approaches to the laboratory diagnosis of rheumatic diseases: Role of molecular and cellular biomarkers. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):324-38 (In Russ.). doi: 10.14412/1995-4484-2016-324-338Aleksandrova EN, Novikov AA, Nasonov EL. Current approaches to the laboratory diagnosis of rheumatic diseases: Role of molecular and cellular biomarkers. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):324-38 (In Russ.). doi: 10.14412/1995-4484-2016-324-338Aleksandrova EN, Novikov AA, Nasonov EL. Current approaches to the laboratory diagnosis of rheumatic diseases: Role of molecular and cellular biomarkers. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):324-38 (In Russ.). doi: 10.14412/1995-4484-2016-324-338Aleksandrova EN, Novikov AA, Nasonov EL. Current approaches to the laboratory diagnosis of rheumatic diseases: Role of molecular and cellular biomarkers. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):324-38 (In Russ.). doi: 10.14412/1995-4484-2016-324-338Avdeeva AS, Artyukhov AS, Dashinimaeva EB, et al. Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):46-55 (In Russ.). doi: 10.14412/1995-4484-2019-46-55Avdeeva AS, Artyukhov AS, Dashinimaeva EB, et al. Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):46-55 (In Russ.). doi: 10.14412/1995-4484-2019-46-55Avdeeva AS, Artyukhov AS, Dashinimaeva EB, et al. Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):46-55 (In Russ.). doi: 10.14412/1995-4484-2019-46-55Avdeeva AS, Artyukhov AS, Dashinimaeva EB, et al. Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):46-55 (In Russ.). doi: 10.14412/1995-4484-2019-46-55Avdeeva AS, Artyukhov AS, Dashinimaeva EB, et al. Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):46-55 (In Russ.). doi: 10.14412/1995-4484-2019-46-55Avdeeva AS, Artyukhov AS, Dashinimaeva EB, et al. Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):46-55 (In Russ.). doi: 10.14412/1995-4484-2019-46-55Avdeeva AS, Artyukhov AS, Dashinimaeva EB, et al. Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):46-55 (In Russ.). doi: 10.14412/1995-4484-2019-46-55Avdeeva AS, Artyukhov AS, Dashinimaeva EB, et al. Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):46-55 (In Russ.). doi: 10.14412/1995-4484-2019-46-55Avdeeva AS, Cherkasova MV, Kusevich DA, et al. Immunological effects of a rituximab biosimilar (Acelbia, BIOCAD) in patients with rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):556-63 (In Russ.). doi: 10.14412/1995-4484-2018-556-563Avdeeva AS, Cherkasova MV, Kusevich DA, et al. Immunological effects of a rituximab biosimilar (Acelbia, BIOCAD) in patients with rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):556-63 (In Russ.). doi: 10.14412/1995-4484-2018-556-563Avdeeva AS, Cherkasova MV, Kusevich DA, et al. Immunological effects of a rituximab biosimilar (Acelbia, BIOCAD) in patients with rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):556-63 (In Russ.). doi: 10.14412/1995-4484-2018-556-563Avdeeva AS, Cherkasova MV, Kusevich DA, et al. Immunological effects of a rituximab biosimilar (Acelbia, BIOCAD) in patients with rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):556-63 (In Russ.). doi: 10.14412/1995-4484-2018-556-563Avdeeva AS, Cherkasova MV, Kusevich DA, et al. Immunological effects of a rituximab biosimilar (Acelbia, BIOCAD) in patients with rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):556-63 (In Russ.). doi: 10.14412/1995-4484-2018-556-563Avdeeva AS, Cherkasova MV, Kusevich DA, et al. Immunological effects of a rituximab biosimilar (Acelbia, BIOCAD) in patients with rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):556-63 (In Russ.). doi: 10.14412/1995-4484-2018-556-563Avdeeva AS, Cherkasova MV, Kusevich DA, et al. Immunological effects of a rituximab biosimilar (Acelbia, BIOCAD) in patients with rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):556-63 (In Russ.). doi: 10.14412/1995-4484-2018-556-563Avdeeva AS, Cherkasova MV, Kusevich DA, et al. Immunological effects of a rituximab biosimilar (Acelbia, BIOCAD) in patients with rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):556-63 (In Russ.). doi: 10.14412/1995-4484-2018-556-563Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8:515-9. doi: 10.1016/j.autrev.2009.01.007Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8:515-9. doi: 10.1016/j.autrev.2009.01.007Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8:515-9. doi: 10.1016/j.autrev.2009.01.007Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8:515-9. doi: 10.1016/j.autrev.2009.01.007Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8:515-9. doi: 10.1016/j.autrev.2009.01.007Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8:515-9. doi: 10.1016/j.autrev.2009.01.007Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8:515-9. doi: 10.1016/j.autrev.2009.01.007Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8:515-9. doi: 10.1016/j.autrev.2009.01.007Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196.Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196.Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196.Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196.Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196.Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196.Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196.Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196.Aleksandrova EN, Avdeyeva AS, Lukina GV, et al. The clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):14-21 (In Russ.). doi: 10.14412/1995-4484-2012-498Aleksandrova EN, Avdeyeva AS, Lukina GV, et al. The clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):14-21 (In Russ.). doi: 10.14412/1995-4484-2012-498Aleksandrova EN, Avdeyeva AS, Lukina GV, et al. The clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):14-21 (In Russ.). doi: 10.14412/1995-4484-2012-498Aleksandrova EN, Avdeyeva AS, Lukina GV, et al. The clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):14-21 (In Russ.). doi: 10.14412/1995-4484-2012-498Aleksandrova EN, Avdeyeva AS, Lukina GV, et al. The clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):14-21 (In Russ.). doi: 10.14412/1995-4484-2012-498Aleksandrova EN, Avdeyeva AS, Lukina GV, et al. The clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):14-21 (In Russ.). doi: 10.14412/1995-4484-2012-498Aleksandrova EN, Avdeyeva AS, Lukina GV, et al. The clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):14-21 (In Russ.). doi: 10.14412/1995-4484-2012-498Aleksandrova EN, Avdeyeva AS, Lukina GV, et al. The clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):14-21 (In Russ.). doi: 10.14412/1995-4484-2012-498Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723-32. doi: 10.1002/art.21650Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723-32. doi: 10.1002/art.21650Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723-32. doi: 10.1002/art.21650Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723-32. doi: 10.1002/art.21650Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723-32. doi: 10.1002/art.21650Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723-32. doi: 10.1002/art.21650Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723-32. doi: 10.1002/art.21650Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723-32. doi: 10.1002/art.21650Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. doi: 10.1002/art.22025Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. doi: 10.1002/art.22025Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. doi: 10.1002/art.22025Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. doi: 10.1002/art.22025Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. doi: 10.1002/art.22025Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. doi: 10.1002/art.22025Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. doi: 10.1002/art.22025Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. doi: 10.1002/art.22025Higashida J, Wun T, Schmidt S. Safety and efficacy of Rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.Higashida J, Wun T, Schmidt S. Safety and efficacy of Rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.Higashida J, Wun T, Schmidt S. Safety and efficacy of Rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.Higashida J, Wun T, Schmidt S. Safety and efficacy of Rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.Higashida J, Wun T, Schmidt S. Safety and efficacy of Rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.Higashida J, Wun T, Schmidt S. Safety and efficacy of Rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.Higashida J, Wun T, Schmidt S. Safety and efficacy of Rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.Higashida J, Wun T, Schmidt S. Safety and efficacy of Rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets Ther. 2008;2:911-6. doi: 10.2147/BTT.S3939Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets Ther. 2008;2:911-6. doi: 10.2147/BTT.S3939Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets Ther. 2008;2:911-6. doi: 10.2147/BTT.S3939Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets Ther. 2008;2:911-6. doi: 10.2147/BTT.S3939Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets Ther. 2008;2:911-6. doi: 10.2147/BTT.S3939Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets Ther. 2008;2:911-6. doi: 10.2147/BTT.S3939Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets Ther. 2008;2:911-6. doi: 10.2147/BTT.S3939Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets Ther. 2008;2:911-6. doi: 10.2147/BTT.S3939Bokareva M, Lindholm C, Zendjanchi K, et al. Efficacy of antiCD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. doi: 10.1111/j.1365-3083.2007.01995.xBokareva M, Lindholm C, Zendjanchi K, et al. Efficacy of antiCD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. doi: 10.1111/j.1365-3083.2007.01995.xBokareva M, Lindholm C, Zendjanchi K, et al. Efficacy of antiCD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. doi: 10.1111/j.1365-3083.2007.01995.xBokareva M, Lindholm C, Zendjanchi K, et al. Efficacy of antiCD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. doi: 10.1111/j.1365-3083.2007.01995.xBokareva M, Lindholm C, Zendjanchi K, et al. Efficacy of antiCD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. doi: 10.1111/j.1365-3083.2007.01995.xBokareva M, Lindholm C, Zendjanchi K, et al. Efficacy of antiCD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. doi: 10.1111/j.1365-3083.2007.01995.xBokareva M, Lindholm C, Zendjanchi K, et al. Efficacy of antiCD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. doi: 10.1111/j.1365-3083.2007.01995.xBokareva M, Lindholm C, Zendjanchi K, et al. Efficacy of antiCD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. doi: 10.1111/j.1365-3083.2007.01995.xToubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20. doi: 10.1136/ard.2006.062505Toubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20. doi: 10.1136/ard.2006.062505Toubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20. doi: 10.1136/ard.2006.062505Toubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20. doi: 10.1136/ard.2006.062505Toubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20. doi: 10.1136/ard.2006.062505Toubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20. doi: 10.1136/ard.2006.062505Toubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20. doi: 10.1136/ard.2006.062505Toubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20. doi: 10.1136/ard.2006.062505Vizioli C, Viana V, Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:667. doi: 10.1136/annrheumdis-2012-eular.519Vizioli C, Viana V, Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:667. doi: 10.1136/annrheumdis-2012-eular.519Vizioli C, Viana V, Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:667. doi: 10.1136/annrheumdis-2012-eular.519Vizioli C, Viana V, Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:667. doi: 10.1136/annrheumdis-2012-eular.519Vizioli C, Viana V, Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:667. doi: 10.1136/annrheumdis-2012-eular.519Vizioli C, Viana V, Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:667. doi: 10.1136/annrheumdis-2012-eular.519Vizioli C, Viana V, Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:667. doi: 10.1136/annrheumdis-2012-eular.519Vizioli C, Viana V, Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:667. doi: 10.1136/annrheumdis-2012-eular.519Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009. doi: 10.1136/rmdopen-2014-000009Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009. doi: 10.1136/rmdopen-2014-000009Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009. doi: 10.1136/rmdopen-2014-000009Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009. doi: 10.1136/rmdopen-2014-000009Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009. doi: 10.1136/rmdopen-2014-000009Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009. doi: 10.1136/rmdopen-2014-000009Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009. doi: 10.1136/rmdopen-2014-000009Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009. doi: 10.1136/rmdopen-2014-000009Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjö gren's Syndrome. Rheumatology (Oxford). 2017 1;56(10):e24-e48. doi: 10.1093/rheumatology/kex166Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjö gren's Syndrome. Rheumatology (Oxford). 2017 1;56(10):e24-e48. doi: 10.1093/rheumatology/kex166Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjö gren's Syndrome. Rheumatology (Oxford). 2017 1;56(10):e24-e48. doi: 10.1093/rheumatology/kex166Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjö gren's Syndrome. Rheumatology (Oxford). 2017 1;56(10):e24-e48. doi: 10.1093/rheumatology/kex166Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjö gren's Syndrome. Rheumatology (Oxford). 2017 1;56(10):e24-e48. doi: 10.1093/rheumatology/kex166Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjö gren's Syndrome. Rheumatology (Oxford). 2017 1;56(10):e24-e48. doi: 10.1093/rheumatology/kex166Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjö gren's Syndrome. Rheumatology (Oxford). 2017 1;56(10):e24-e48. doi: 10.1093/rheumatology/kex166Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjö gren's Syndrome. Rheumatology (Oxford). 2017 1;56(10):e24-e48. doi: 10.1093/rheumatology/kex166Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-28. doi: 10.1016/S1474-4422(18)30254-0Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-28. doi: 10.1016/S1474-4422(18)30254-0Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-28. doi: 10.1016/S1474-4422(18)30254-0Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-28. doi: 10.1016/S1474-4422(18)30254-0Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-28. doi: 10.1016/S1474-4422(18)30254-0Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-28. doi: 10.1016/S1474-4422(18)30254-0Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-28. doi: 10.1016/S1474-4422(18)30254-0Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-28. doi: 10.1016/S1474-4422(18)30254-0Clinical Commissioning Policy: Rituximab for the treatment of dermatomyositis and polymyositis. NHS England 16036/P, 2017.Clinical Commissioning Policy: Rituximab for the treatment of dermatomyositis and polymyositis. NHS England 16036/P, 2017.Clinical Commissioning Policy: Rituximab for the treatment of dermatomyositis and polymyositis. NHS England 16036/P, 2017.Clinical Commissioning Policy: Rituximab for the treatment of dermatomyositis and polymyositis. NHS England 16036/P, 2017.Clinical Commissioning Policy: Rituximab for the treatment of dermatomyositis and polymyositis. NHS England 16036/P, 2017.Clinical Commissioning Policy: Rituximab for the treatment of dermatomyositis and polymyositis. NHS England 16036/P, 2017.Clinical Commissioning Policy: Rituximab for the treatment of dermatomyositis and polymyositis. NHS England 16036/P, 2017.Clinical Commissioning Policy: Rituximab for the treatment of dermatomyositis and polymyositis. NHS England 16036/P, 2017.Fernandez-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algoritm Group. Treatment Algoritm for Systemic Sclerosis According to Expert. Arthritis Rheum. 2018;70:1820-8. doi: 10.1002/art.40560Fernandez-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algoritm Group. Treatment Algoritm for Systemic Sclerosis According to Expert. Arthritis Rheum. 2018;70:1820-8. doi: 10.1002/art.40560Fernandez-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algoritm Group. Treatment Algoritm for Systemic Sclerosis According to Expert. Arthritis Rheum. 2018;70:1820-8. doi: 10.1002/art.40560Fernandez-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algoritm Group. Treatment Algoritm for Systemic Sclerosis According to Expert. Arthritis Rheum. 2018;70:1820-8. doi: 10.1002/art.40560Fernandez-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algoritm Group. Treatment Algoritm for Systemic Sclerosis According to Expert. Arthritis Rheum. 2018;70:1820-8. doi: 10.1002/art.40560Fernandez-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algoritm Group. Treatment Algoritm for Systemic Sclerosis According to Expert. Arthritis Rheum. 2018;70:1820-8. doi: 10.1002/art.40560Fernandez-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algoritm Group. Treatment Algoritm for Systemic Sclerosis According to Expert. Arthritis Rheum. 2018;70:1820-8. doi: 10.1002/art.40560Fernandez-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algoritm Group. Treatment Algoritm for Systemic Sclerosis According to Expert. Arthritis Rheum. 2018;70:1820-8. doi: 10.1002/art.40560

The authors declare that there are no conflicts of interest present.